<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Haloperidol: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Haloperidol: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Haloperidol: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12529" href="/d/html/12529.html" rel="external">see "Haloperidol: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13347" href="/d/html/13347.html" rel="external">see "Haloperidol: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F6697563"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Increased mortality in elderly patients with dementia-related psychosis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration, 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was approximately 4.5%, compared with a rate of approximately 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Haloperidol is not approved for the treatment of patients with dementia-related psychosis.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F178552"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Haldol Decanoate;</li>
<li>Haldol [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867099"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Haloperidol [DSC];</li>
<li>TEVA-Haloperidol</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F178603"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        First Generation (Typical) Antipsychotic</li></ul></div>
<div class="block doa drugH1Div" id="F178557"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> IV administration is associated with dose-dependent QT prolongation at doses &gt;2 mg and the risk of rare, but potentially fatal, cardiac arrhythmia; increased monitoring is necessary prior to and during administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20142454','lexi-content-ref-Jibson.1','lexi-content-ref-20394022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20142454','lexi-content-ref-Jibson.1','lexi-content-ref-20394022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> All doses are expressed as the equivalent amounts of haloperidol base. Although manufacturer's labeling includes a maximum dose of up to 100 mg/day, doses &gt;30 mg/day are in general not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Moore.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Moore.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b>Concomitant IM or IV antiparkinsonism medications (eg, benztropine, diphenhydramine) may be useful for preventing acute dystonic reactions to short-acting IM/IV haloperidol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9359953','lexi-content-ref-7494570','lexi-content-ref-19955388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9359953','lexi-content-ref-7494570','lexi-content-ref-19955388'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="21dde351-f095-4a55-8b49-bf5298b1e8e6">Agitation/Aggression associated with psychiatric disorders, substance intoxication, or other organic causes</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Agitation/Aggression (severe, acute) associated with psychiatric disorders (eg, schizophrenia), substance intoxication, or other organic causes (off-label use):</b>
<b>Note:</b> Antipsychotics are appropriate when psychosis is suspected to be the primary cause of agitation/aggression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22461918','lexi-content-ref-22834451']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22461918','lexi-content-ref-22834451'])">Ref</a></span>). Avoid in suspected or confirmed intoxications with anticholinergic substances; other agents are used preferentially in some intoxications (eg, stimulants) or alcohol withdrawal. Depending on presentation, may combine with a benzodiazepine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Moore.1','lexi-content-ref-Suh.1','lexi-content-ref-22461918']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Moore.1','lexi-content-ref-Suh.1','lexi-content-ref-22461918'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IM, IV (off-label route) (lactate injection): 2 to 10 mg; repeat dose every ≥15 minutes until acute symptoms are controlled; once acute symptoms are controlled, may repeat every 0.5 to 6 hours as needed; up to 30 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3813167','lexi-content-ref-29885904','lexi-content-ref-22544013','lexi-content-ref-Moore.1','lexi-content-ref-28758203','lexi-content-ref-22461918','lexi-content-ref-21601409']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3813167','lexi-content-ref-29885904','lexi-content-ref-22544013','lexi-content-ref-Moore.1','lexi-content-ref-28758203','lexi-content-ref-22461918','lexi-content-ref-21601409'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: 2 to 10 mg; repeat dose every 6 hours as needed; up to 30 mg/day. A lower initial dose of 0.5 to 1 mg may be sufficient for some patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Moore.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Moore.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1969751f-c027-4072-874e-d4df29195cbe">Bipolar disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bipolar disorder:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute mania, episodes with mixed features and acute hypomania (either as monotherapy or as adjunctive therapy) (off-label use): Note:</b> Haloperidol may worsen depressive symptoms. It is not recommended for the treatment of acute bipolar major depression or for maintenance in bipolar disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stovall.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stovall.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Initial: 2 to 15 mg/day <b>or</b> 0.2 mg/kg/day (up to 15 mg/day), in 1 or 2 divided doses. May increase dose based on response and tolerability in increments of ≤5 mg as frequently as every 2 days up to 30 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22841129','lexi-content-ref-8601548','lexi-content-ref-12091192','lexi-content-ref-Stovall.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22841129','lexi-content-ref-8601548','lexi-content-ref-12091192','lexi-content-ref-Stovall.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cef3d47d-a014-4149-a4c1-7167fc2856a4">Chemotherapy-induced breakthrough nausea and vomiting</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chemotherapy-induced breakthrough nausea and vomiting (alternative therapy) (off-label use):</b>
<b>Note:</b> May be used as an adjunct to standard antiemetic regimens for breakthrough nausea/vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hesketh.1','lexi-content-ref-18391612']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hesketh.1','lexi-content-ref-18391612'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral, IV (off-label route) (lactate injection): 0.5 to 1 mg every 6 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18391612']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18391612'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fe1ae4e5-73fd-4d98-85e5-a6c136ba052d">Delirium, hyperactive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Delirium, hyperactive (treatment): Note:</b> Nonpharmacologic interventions and treatment of underlying conditions are initial steps to prevent and manage delirium. Antipsychotics may be used as short-term adjunctive treatment if distressing symptoms (eg, agitation, anxiety, combative behavior) are present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30113379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30113379'])">Ref</a></span>). Reassess daily for continued need; consider discontinuation and/or taper as symptoms resolve, especially at transitions of care to prevent unnecessary continuation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28049388','lexi-content-ref-26818629','lexi-content-ref-Tietze.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28049388','lexi-content-ref-26818629','lexi-content-ref-Tietze.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>ICU (off-label use): </b>IV (off-label route), IM (lactate injection): Initial range: 0.5 to 20 mg depending on degree of agitation (mild: 0.5 to 2.5 mg; moderate: 2 to 5 mg; severe: 10 to 20 mg); if inadequate response, may repeat or increase bolus dose every 15 to 30 minutes until calm achieved, then administer a maintenance dose (~25% of total loading dose needed to achieve calm) every 6 to 12 hours if needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36286254','lexi-content-ref-30346242','lexi-content-ref-Tesar.1988','lexi-content-ref-Tietze.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36286254','lexi-content-ref-30346242','lexi-content-ref-Tesar.1988','lexi-content-ref-Tietze.1'])">Ref</a></span>). <b>Note: </b>Continuous infusions have been used for refractory symptoms; regimens vary. One regimen includes an optional loading dose of 2.5 mg, followed by 0.5 to 2 mg/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19454032']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19454032'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Non-ICU (off-label use): </b>IM, IV (off-label route) (lactate injection), Oral: Initial: 0.5 to 1 mg; if needed, may repeat every 30 minutes until calm. Maximum 5 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Francis.1','lexi-content-ref-23926422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Francis.1','lexi-content-ref-23926422'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3a1b96c0-b72b-4126-b53b-a21590b80f6f">Nausea and vomiting in advanced or terminal illness</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nausea and vomiting in advanced or terminal illness (palliative care) (alternative agent) (off-label use): </b>
<b>Note:</b> Identify and treat potentially reversible causes; used in conjunction with other agents/treatments in bowel obstruction-associated symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-DelFabbro.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-DelFabbro.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IV, SubQ (off-label routes) (lactate injection), Oral: 0.5 to 2 mg every 6 to 8 hours; for nausea associated with bowel obstruction, may titrate up to 20 mg/day IV in divided doses if needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-DelFabbro.1','lexi-content-ref-Harman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-DelFabbro.1','lexi-content-ref-Harman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous SubQ infusion (off-label route) (lactate injection): Typical range for initial treatment: 1 to 5 mg per 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19093700','lexi-content-ref-Mercadante.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19093700','lexi-content-ref-Mercadante.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dd4192a2-1bd0-4e14-bab4-4c1d8d01644e">Postoperative nausea and vomiting, prevention, moderate- to high-risk patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postoperative nausea and vomiting, prevention, moderate- to high-risk patients (alternative agent) (off-label use):</b>
<b>Note: </b>In general, combined with one or more other prophylactic interventions.</p>
<p style="text-indent:-2em;margin-left:4em;">IV (off-label route) (lactate injection): 0.5 to 2 mg as a single dose after induction of anesthesia or at the end of surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32467512','lexi-content-ref-15564955','lexi-content-ref-Feinleib.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32467512','lexi-content-ref-15564955','lexi-content-ref-Feinleib.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c642acd-fa55-4d9d-a66b-f25756b729c3">Schizophrenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Schizophrenia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Oral, IM, IV (lactate injection; off-label route [IV]): Initial: 2 to 10 mg/day in 1 to 3 divided doses; adjust dose based on response and tolerability to a usual dose of 2 to 20 mg/day (typically ≤10 mg/day). Doses &gt;30 mg/day are <b>not </b>recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14645311','lexi-content-ref-Stroup.1','lexi-content-ref-23216388','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14645311','lexi-content-ref-Stroup.1','lexi-content-ref-23216388','lexi-content-ref-Manu.1'])">Ref</a></span>). <b>Note:</b> In a first psychotic episode, a lower dose (eg, 1 to 4 mg/day) may be sufficient (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23216388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23216388'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IM (decanoate ER suspension): <b>Note:</b> Establish tolerability using oral haloperidol prior to initiating IM decanoate injection.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Regimen <b>with </b>overlapping of oral haloperidol:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Initial: 10 to 20 times the daily oral dose. If the initial dose conversion requires &gt;100 mg ER injection, administer the dose in 2 injections with a maximum of 100 mg for first injection and the remainder given in 3 to 7 days. Maximum total initial dose: 450 mg.</p>
<p style="text-indent:-2em;margin-left:8em;">Oral overlap: Following the first ER decanoate dose, taper the oral dose by ~25% at weekly intervals during the second or third month of decanoate treatment. Adjust oral dose and rate of tapering based on clinical response and tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lauriello.1','lexi-content-ref-16822092']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lauriello.1','lexi-content-ref-16822092'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance dose: Adjust dose based on response and tolerability; usual maintenance dose is 10 to 15 times the previous daily oral dose administered at 4-week intervals. Maximum dose: 450 mg every 4 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Alternative regimen <b>without </b>overlap of oral haloperidol</i>: <b>Note:</b> Discontinue oral haloperidol immediately prior to the first injection when using this regimen.</p>
<p style="text-indent:-2em;margin-left:8em;">Initial: 20 times the daily oral dose. If the initial dose conversion requires &gt;100 mg ER injection, administer the dose in 2 injections with a maximum of 100 mg for the first injection and the remainder given in 3 to 7 days.</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance dose: Reduce the ER decanoate dose during the second and third months (eg, by ~25% each month), then continue to adjust based on response and tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2371365','lexi-content-ref-7907570']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2371365','lexi-content-ref-7907570'])">Ref</a></span>). Usual maintenance dose is 10 to 15 times the previous daily oral dose administered at 4-week intervals. Maximum dose: 450 mg every 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ea2828b9-8d09-48ca-bc5f-04b29b0e7996">Tourette syndrome, management of tics</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tourette syndrome, management of tics (alternative agent):</b> Oral: Initial: 1 to 2 mg/day in 1 to 3 divided doses; may increase dose based on response and tolerability in increments of 0.5 to 2 mg every 2 to 3 days up to 12 mg/day. <b>Note: </b>Although manufacturer's labeling includes a maximum dose of up to 100 mg/day, doses ≥12 mg/day are not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31061208']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31061208'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosing conversion: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>IM (lactate injection) to oral:</i> Use the total IM (as lactate) dose administered in the preceding 24 hours as an initial approximation of the total daily dose requirement for the oral formulation. Initiate the first oral dose within 12 to 24 hours of the last IM (as lactate) dose. Adjust dose based on response and tolerability. <b>Note:</b> Bioavailability of oral administration is about 60% to 70% relative to short-acting lactate injection; dose adjustment may be needed when switching from short-acting injection to oral (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Jibson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Jibson.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Oral to IM (as decanoate): </i>See Schizophrenia dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Discontinuation of therapy:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> In the treatment of chronic psychiatric disease, switching therapy rather than discontinuation is generally advised if side effects are intolerable or treatment is not effective. If patient insists on stopping treatment, gradual dose reduction (ie, over several weeks to months) is advised to detect a re-emergence of symptoms and to avoid withdrawal reactions (eg, agitation, alternating feelings of warmth and chill, anxiety, diaphoresis, dyskinesias, GI symptoms, insomnia, irritability, myalgia, paresthesia, psychosis, restlessness, rhinorrhea, tremor, vertigo) unless discontinuation is due to significant adverse effects. Monitor closely to allow for detection of prodromal symptoms of disease recurrence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516','lexi-content-ref-17650054','lexi-content-ref-32670542','lexi-content-ref-Post.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516','lexi-content-ref-17650054','lexi-content-ref-32670542','lexi-content-ref-Post.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Long-acting injectable:</b> Switching to other treatments is generally advised if side effects are intolerable or treatment is not effective. However, if a patient insists on stopping treatment, gradual dose reduction to avoid withdrawal reactions is generally <b>not</b> needed with long-acting injectable antipsychotics. The risk of withdrawal symptoms from discontinuation of long-acting injectables is low because the rate of drug elimination is slow. Monitor closely to allow for detection of prodromal symptoms of disease recurrence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516','lexi-content-ref-23343447','lexi-content-ref-Steinman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516','lexi-content-ref-23343447','lexi-content-ref-Steinman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Switching antipsychotics:</b></i> An optimal universal strategy for switching antipsychotic drugs has not been established. Strategies include cross-titration (gradually discontinuing the first antipsychotic while gradually increasing the new antipsychotic) and abrupt change (abruptly discontinuing the first antipsychotic and either increasing the new antipsychotic gradually or starting it at a treatment dose). In patients with schizophrenia at high risk of relapse, the current medication may be maintained at full dose as the new medication is increased (ie, overlap); once the new medication is at therapeutic dose, the first medication is gradually decreased and discontinued over 1 to 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23821039','lexi-content-ref-15949658','lexi-content-ref-28044008']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23821039','lexi-content-ref-15949658','lexi-content-ref-28044008'])">Ref</a></span>). Based upon clinical experience, some experts generally prefer cross-titration and overlap approaches rather than abrupt change (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stroup.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stroup.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991415"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: </b>Mild to severe impairment: No dosage adjustment necessary (~1% of drug eliminated in urine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10628896','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10628896','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzed (large volume of distribution): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>); use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (large volume of distribution): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>); use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Unlikely to be dialyzed (large volume of distribution): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained low-efficiency diafiltration):</b> Unlikely to be dialyzed (large volume of distribution): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988647"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, haloperidol concentrations may increase in patients with hepatic impairment because it is primarily metabolized by the liver and protein binding may decrease.</p></div>
<div class="block doe drugH1Div" id="F178558"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Avoid for behavioral problems associated with dementia or delirium unless alternative nonpharmacologic therapies have failed and patient may harm self or others. If used, consider deprescribing attempts to assess continued need and/or lowest effective dose. Of note, use in certain indications (eg, schizophrenia, bipolar disorder) may be appropriate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Refer to adult dosing for indication-specific dosing. For hyperactive delirium or acute agitation, consider dosages in the lower initial range of recommended adult dosing (eg, 0.5 to 1 mg) and increase monitoring due to greater risks for adverse effects, including sedation and QTc prolongation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36113417','lexi-content-ref-23653156']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36113417','lexi-content-ref-23653156'])">Ref</a></span>). Dosages in the lower range of recommended adult dosing are generally sufficient with late-onset schizophrenia or psychosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10671383']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10671383'])">Ref</a></span>).</p></div>
<div class="block dop drugH1Div" id="F178580"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13347" href="/d/html/13347.html" rel="external">see "Haloperidol: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Individualize dosing based on patient response. Gradually decrease dose to the lowest effective maintenance dosage once a satisfactory therapeutic response is obtained. Dosing presented as fixed (mg) dosing and weight-based (mg/<b>kg</b>) dosing; use caution when prescribing and dispensing.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="419949a0-7063-499a-bfea-d3f0bc006ef6">Acute agitation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute agitation:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Recommended for acute agitation in patients with suspected ethanol, benzodiazepine, or unknown intoxication, a known psychiatric disorder, hallucinations, or unknown etiology (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30881565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30881565'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Weight-directed: Children and Adolescents: Oral: 0.025 to 0.075 mg/kg/dose; may repeat dose every 1 to 2 hours; not to exceed maximum daily dose: Patients ≤40 kg: 6 mg/<b>day</b>; patients &gt;40 kg: 15 mg/<b>day</b>. In adults, usual <b>total</b> dose required is 10 to 20 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30881565','lexi-content-ref-31871244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30881565','lexi-content-ref-31871244'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Fixed dose: Oral: Children: 0.5 to 2 mg; Adolescents: 2 to 5 mg; may repeat dose every 1 to 2 hours; not to exceed maximum daily dose: Patients ≤40 kg: 6 mg/<b>day</b>; patients &gt;40 kg: 15 mg/<b>day</b>. In adults, usual <b>total</b> dose required is 10 to 20 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30881565','lexi-content-ref-31871244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30881565','lexi-content-ref-31871244'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Parenteral: Recommended for acute agitation in patients with psychosis or mania, or suspected ethanol, benzodiazepine, or unknown intoxication, a known psychiatric disorder, hallucinations, or unknown etiology (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30881565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30881565'])">Ref</a></span>); if extrapyramidal symptoms (EPS) are a concern, consider concomitant diphenhydramine.</p>
<p style="text-indent:-2em;margin-left:6em;">Weight-directed: Children and Adolescents: IM (lactate, immediate release): 0.025 to 0.075 mg/kg/dose; may repeat dose every 20 to 30 minutes; not to exceed maximum daily dose: Patients ≤40 kg: 6 mg/<b>day</b>; patients &gt;40 kg: 15 mg/<b>day</b>. In adults, usual <b>total</b> dose required is 10 to 20 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30881565','lexi-content-ref-31871244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30881565','lexi-content-ref-31871244'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Fixed dose: Children and Adolescents: IM (lactate, immediate release): Children: 0.5 to 2 mg; Adolescents: 2 to 5 mg; may repeat dose every 20 to 30 minutes; not to exceed maximum daily dose: Patients ≤40 kg: 6 mg/<b>day</b>; patients &gt;40 kg: 15 mg/<b>day</b>. In adults, usual <b>total</b> dose required is 10 to 20 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30881565','lexi-content-ref-31871244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30881565','lexi-content-ref-31871244'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="41c35bee-41f5-4f90-a7aa-13199c584f94">Agitation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Agitation (palliative care):</b> Limited data available: Children ≥3 years and Adolescents: Oral: 0.01 mg/<b>kg</b>/dose 3 times daily as needed; to manage new-onset acute episode: 0.025 to 0.05 mg/<b>kg</b> once then may repeat 0.025 mg/<b>kg</b>/dose in one hour as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2517f240-ef88-4c4e-b9c5-734e8af30e52">Behavior disorders, nonpsychotic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Behavior disorders, nonpsychotic: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For treatment of bipolar disorder (acute mania, nonpsychotic), haloperidol is not considered first line; initially second-generation antipsychotics and mood stabilizers are preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17195735','lexi-content-ref-26237252']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17195735','lexi-content-ref-26237252'])">Ref</a></span>). For management of disruptive behavior disorders without psychosis, therapy typically initiated with stimulants; haloperidol (first-generation antipsychotics) is no longer routinely used as initial therapy but may be necessary in refractory or complex cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-McVoy.1','lexi-content-ref-22196314']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-McVoy.1','lexi-content-ref-22196314'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥3 years and Adolescents: Limited data available in ages &gt;12 years: Oral: Initial: 0.5 mg/day in 2 to 3 divided doses; may increase total daily dose by 0.5 mg every 5 to 7 days to usual maintenance range of 0.05 to 0.075 mg/<b>kg</b>/day in 2 to 3 divided doses; in the management of disruptive behavior disorders, a range of 0.5 to 10 mg/day has been suggested; maximum daily dose for patients 3 to 12 years of age and ≤40 kg: 6 mg/<b>day</b> in divided doses (children with severe, nonpsychotic disturbance did not show improvement with doses &gt;6 mg/day); a maximum daily dose of 15 mg/<b>day</b> in divided doses has been suggested in adolescents with psychosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1','lexi-content-ref-Kliegman.2','lexi-content-ref-McVoy.1','lexi-content-ref-4887476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1','lexi-content-ref-Kliegman.2','lexi-content-ref-McVoy.1','lexi-content-ref-4887476'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a49893af-7ac7-4fb4-b93d-6e3425480a1d">Delirium, critical care setting</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Delirium, critical care setting:</b> Limited data available; optimal dose not established:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Antipsychotics may be used as short-term adjunctive treatment; reassess frequently for continued need and consider taper/discontinuation as symptoms resolve (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23639666']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23639666'])">Ref</a></span>). The administration of IV haloperidol is associated with QT prolongation and torsades de pointes; in adults without concomitant risk factors, this effect is dose dependent and was reported with cumulative IV doses ≥2 mg; in all patients, increased monitoring is necessary at baseline and during administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20142454','lexi-content-ref-20394022','lexi-content-ref-23639666']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20142454','lexi-content-ref-20394022','lexi-content-ref-23639666'])">Ref</a></span>); ensure appropriate monitoring including extrapyramidal symptoms (EPS) effects.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 months, Children, and Adolescents: IV (lactate, immediate release): <b>Note:</b> Reported experience in infants is very limited and suggests that lower doses may be required:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Loading dose: </i>
<b>Note:</b> Dosing is presented as a fixed dose (not a weight-based dose).</p>
<p style="text-indent:-2em;margin-left:8em;">Weight 3.5 to &lt;10 kg: IV: 0.05 mg (fixed dose) infused slowly over 30 to 45 minutes; may repeat twice for a maximum of 3 total doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17457571','lexi-content-ref-20689925','lexi-content-ref-29239979']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17457571','lexi-content-ref-20689925','lexi-content-ref-29239979'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Weight ≥10 kg: IV: 0.15 to 0.25 mg (fixed dose) infused slowly over 30 to 45 minutes; may repeat twice for a maximum of 3 total doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Fuhrman.1','lexi-content-ref-17457571','lexi-content-ref-29239979']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Fuhrman.1','lexi-content-ref-17457571','lexi-content-ref-29239979'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance dose: </i>
<b>Note:</b> Dosing is presented as weight-based dosing (ie, mg/<b>kg/day</b>) administered in divided doses:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note</b>: Use lowest effective dose, evaluate delirium symptoms daily, optimize nonpharmacologic treatments and discontinue/titrate therapy after clinical improvement and resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23639666']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23639666'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">Weight 3.5 to &lt;10 kg: IV: Initial: 0.01 to 0.05 mg/<b>kg/day</b> in divided doses every 6 to 24 hours; may increase dose based on clinical response; higher doses have been associated with an increased incidence of EPS and sedation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17457571','lexi-content-ref-20689925','lexi-content-ref-29239979']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17457571','lexi-content-ref-20689925','lexi-content-ref-29239979'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Weight ≥10 kg: IV: Initial: 0.05 to 0.5 mg/<b>kg</b>/<b>day</b> in divided doses every 6 to 24 hours; may increase dose based on clinical response; higher doses have been associated with an increased incidence of EPS and sedation; a maximum single pediatric dose is not defined in the literature; in adults, single doses of 10 mg are reserved for severe cases of delirium and up to 20 mg in some cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8808357','lexi-content-ref-Fuhrman.1','lexi-content-ref-11866368','lexi-content-ref-17457571','lexi-content-ref-20689925','lexi-content-ref-29239979','lexi-content-ref-Tesar.1988']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8808357','lexi-content-ref-Fuhrman.1','lexi-content-ref-11866368','lexi-content-ref-17457571','lexi-content-ref-20689925','lexi-content-ref-29239979','lexi-content-ref-Tesar.1988'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="523b488f-3a6d-4eaa-8927-e289ba66da6a">Psychotic disorders</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Psychotic disorders: Note:</b> Not generally used as initial therapy for management of schizophrenia in pediatric patients; second-generation (atypical) antipsychotics typically preferred first line (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23972700','lexi-content-ref-28764561','lexi-content-ref-32186837']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23972700','lexi-content-ref-28764561','lexi-content-ref-32186837'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥3 years and Adolescents: Limited data available in ages &gt;12 years: Oral: Initial: 0.5 mg/day in 2 to 3 divided doses; increase total daily dose by 0.5 mg every 5 to 7 days to usual maintenance range of 0.05 to 0.15 mg/<b>kg</b>/day in 2 to 3 divided doses; in pediatric schizophrenia efficacy trials (reported mean ages: 9 to 16 years), a mean dose range of 8 to 10 mg/day was reported; higher doses may be necessary in severe or refractory cases; maximum dose not established in children; in adolescents, maximum daily dose: 15 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12721815','lexi-content-ref-McVoy.1','lexi-content-ref-4887476','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12721815','lexi-content-ref-McVoy.1','lexi-content-ref-4887476','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="308cbb9f-ebfb-4bbc-90ee-cd1c4f6c900c">Tourette syndrome, tic disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tourette syndrome, tic disorder: Note:</b> Compared to placebo, haloperidol is probably more likely than placebo to reduce tic severity; a higher risk of drug-induced movement disorders (compared to placebo) was observed in Tourette syndrome/tic trials with haloperidol; may be considered when treatment benefits outweigh risks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31061208']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31061208'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥3 years and Adolescents: Oral: Initial: 0.25 to 0.5 mg/day in 2 to 3 divided doses; increase daily dose by 0.25 to 0.5 mg every 5 to 7 days to usual daily dose maintenance range of 1 to 4 mg/day in 2 to 3 divided doses has been reported (weight-directed maintenance per the manufacturer: 0.05 to 0.075 mg/kg/day in 2 to 3 divided doses); maximum daily dose: 15 mg/<b>day</b>; however, children with severe, nonpsychotic disturbance did not show improvement with doses &gt;6 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24290467','lexi-content-ref-21445724','lexi-content-ref-16554257','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24290467','lexi-content-ref-21445724','lexi-content-ref-16554257','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation</b>
<b> of psychosis therapy: </b>Children and Adolescents: The manufacturer and American Academy of Child and Adolescent Psychiatry (AACAP), American Psychiatric Association (APA), Canadian Psychiatric Association (CPA), National Institute for Health and Care Excellence (NICE), and World Federation of Societies of Biological Psychiatry (WFSBP) guidelines recommend gradually tapering antipsychotics to avoid withdrawal symptoms and minimize the risk of relapse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17195735','lexi-content-ref-15000267','lexi-content-ref-23821039','lexi-content-ref-16529334','lexi-content-ref-26065063','lexi-content-ref-22834451']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17195735','lexi-content-ref-15000267','lexi-content-ref-23821039','lexi-content-ref-16529334','lexi-content-ref-26065063','lexi-content-ref-22834451'])">Ref</a></span>); risk for withdrawal symptoms may be highest with highly anticholinergic or dopaminergic antipsychotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23821039']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23821039'])">Ref</a></span>). When stopping antipsychotic therapy in patients with schizophrenia, the CPA guidelines recommend a gradual taper over 6 to 24 months and the APA guidelines recommend reducing the dose by 10% each month (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15000267','lexi-content-ref-16529334']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15000267','lexi-content-ref-16529334'])">Ref</a></span>). Continuing antiparkinsonism agents for a brief period after discontinuation may prevent withdrawal symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23821039']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23821039'])">Ref</a></span>). When switching antipsychotics, three strategies have been suggested: Cross-titration (gradually discontinuing the first antipsychotic while gradually increasing the new antipsychotic), overlap and taper (maintaining the dose of the first antipsychotic while gradually increasing the new antipsychotic, then tapering the first antipsychotic), and abrupt change (abruptly discontinuing the first antipsychotic and either increasing the new antipsychotic gradually or starting it at a treatment dose). Evidence supporting ideal switch strategies and taper rates is limited and results are conflicting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23821039','lexi-content-ref-15949658']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23821039','lexi-content-ref-15949658'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51112873"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥3 years and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis/peritoneal dialysis: Supplemental dose is not necessary.</p></div>
<div class="block dohp drugH1Div" id="F51112874"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥3 years and Adolescents: There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block arsc drugH1Div" id="F54997492"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Extrapyramidal symptoms</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Haloperidol commonly causes extrapyramidal symptoms (EPS), also known as drug-induced movement disorders, in all ages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11866368','lexi-content-ref-25183567','lexi-content-ref-24898718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11866368','lexi-content-ref-25183567','lexi-content-ref-24898718'])">Ref</a></span>). Antipsychotics can cause 4 main EPS: Acute <b>dystonia</b>, drug-induced <b>parkinsonism</b>, <b>akathisia</b>, and <b>tardive dyskinesia </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12927004','lexi-content-ref-21172575','lexi-content-ref-Chen.2012','lexi-content-ref-26392457','lexi-content-ref-18344731','lexi-content-ref-11866368','lexi-content-ref-20187598','lexi-content-ref-25183567','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12927004','lexi-content-ref-21172575','lexi-content-ref-Chen.2012','lexi-content-ref-26392457','lexi-content-ref-18344731','lexi-content-ref-11866368','lexi-content-ref-20187598','lexi-content-ref-25183567','lexi-content-ref-28721057'])">Ref</a></span>). EPS presenting as <b>dysphagia</b>, esophageal dysmotility, or <b>pulmonary</b>
<b>aspiration</b>, have also been reported with antipsychotics, which may not be recognized as EPS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29955499','lexi-content-ref-17024549','lexi-content-ref-19047493','lexi-content-ref-14565800']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29955499','lexi-content-ref-17024549','lexi-content-ref-19047493','lexi-content-ref-14565800'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> EPS: Dose-related; due to antagonism of dopaminergic D<sub>2</sub> receptors in nigrostriatal pathways; high levels of dopamine 2 receptor occupancy have been observed for haloperidol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22281201','lexi-content-ref-7831996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22281201','lexi-content-ref-7831996'])">Ref</a></span>). Tardive dyskinesia: Time related (delayed); results from chronic exposure to dopamine 2 receptor antagonists leading to up-regulation of these receptors over time (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23858394']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23858394'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Antipsychotics in general:</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Acute dystonia:</span> Rapid; in the majority of cases, dystonia usually occurs within the first 5 days after initiating antipsychotic therapy (and even with the first dose, particularly in patients receiving parenteral antipsychotics) or a dosage increase (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Drug-induced parkinsonism:</span> Varied; onset may be delayed from days to weeks, with 50% to 75% of cases occurring within 1 month and 90% within 3 months of antipsychotic initiation, a dosage increase, or a change in the medication regimen (such as adding another antipsychotic agent or discontinuing an anticholinergic medication) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Akathisia:</span> Varied; may begin within several days after antipsychotic initiation but usually increases with treatment duration, occurring within 1 month in up to 50% of cases, and within 3 months in 90% of cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Tardive dyskinesia:</span> Delayed; symptoms usually appear after 1 to 2 years of continuous exposure to a dopamine 2 receptor antagonist, and almost never before 3 months, with an insidious onset, evolving into a full syndrome over days and weeks, followed by symptom stabilization, and then a chronic waxing and waning of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23858394']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23858394'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Esophageal dysfunction (associated with EPS)</span>: Varied; ranges from weeks to months following initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14565800']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14565800'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">EPS (in general):</p>
<p style="text-indent:-2em;margin-left:8em;">• Prior history of EPS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506','lexi-content-ref-15000267','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506','lexi-content-ref-15000267','lexi-content-ref-28721057'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506','lexi-content-ref-15000267','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506','lexi-content-ref-15000267','lexi-content-ref-28721057'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Specific antipsychotic: Haloperidol has a high propensity to cause EPS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15000267','lexi-content-ref-20187598','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15000267','lexi-content-ref-20187598','lexi-content-ref-28721057'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Acute dystonia:</p>
<p style="text-indent:-2em;margin-left:8em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10473482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10473482'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Young age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10473482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10473482'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Drug-induced parkinsonism:</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Akathisia:</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher antipsychotic dosages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Polypharmacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Mood disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Tardive dyskinesia:</p>
<p style="text-indent:-2em;margin-left:8em;">• Age &gt;55 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Cognitive impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant treatment with anticholinergic medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Diagnosis of schizophrenia or affective disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31325958']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31325958'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Female sex (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17390261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17390261'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Greater total antipsychotic exposure (especially first-generation antipsychotics) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17390261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17390261'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of extrapyramidal symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Substance misuse or dependence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Race (White or African descent). <b>Note:</b> Although early literature supported race as a potential risk factor for tardive dyskinesia (Morgenstern 1993), newer studies have challenged this assertion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28146614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28146614'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Esophageal dysfunction (associated with EPS):</p>
<p style="text-indent:-2em;margin-left:8em;">• Certain comorbidities such as neurologic degenerative disease, dementia, stroke, Parkinson disease, or myasthenia gravis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29955499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29955499'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older adults &gt;75 years of age (may be risk factor due to age-related muscle atrophy, cognitive impairment, reduced esophageal peristalsis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29955499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29955499'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hematologic abnormalities</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Leukopenia</b>, <b>neutropenia</b>, and <b>thrombocytopenia</b> have been reported rarely with haloperidol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3567823','lexi-content-ref-513257','lexi-content-ref-16401649','lexi-content-ref-10798826','lexi-content-ref-10958256','lexi-content-ref-32671642','lexi-content-ref-24930415','lexi-content-ref-31142911']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3567823','lexi-content-ref-513257','lexi-content-ref-16401649','lexi-content-ref-10798826','lexi-content-ref-10958256','lexi-content-ref-32671642','lexi-content-ref-24930415','lexi-content-ref-31142911'])">Ref</a></span>). <b>Agranulocytosis </b>and <b>pancytopenia</b> have also been reported very rarely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3819263','lexi-content-ref-32671642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3819263','lexi-content-ref-32671642'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Unclear and poorly understood (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3819263','lexi-content-ref-10958256','lexi-content-ref-24930415','lexi-content-ref-31142911']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3819263','lexi-content-ref-10958256','lexi-content-ref-24930415','lexi-content-ref-31142911'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; in general, drug-induced neutropenia usually manifests after 1 or 2 weeks of exposure and agranulocytosis usually appears 3 to 4 weeks following initiation of therapy; however, the onset may be insidious (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18098216','lexi-content-ref-3819263']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18098216','lexi-content-ref-3819263'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• History of drug-induced leukopenia/neutropenia or preexisting low WBC or absolute neutrophil count</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18098216','lexi-content-ref-3819263','lexi-content-ref-32671642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18098216','lexi-content-ref-3819263','lexi-content-ref-32671642'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyperprolactinemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Haloperidol commonly causes <b>hyperprolactinemia</b>, which may lead to <b>gynecomastia</b>, <b>galactorrhea </b>
<b>not associated with childbirth</b>, <b>amenorrhea</b>, <b>sexual disorder</b>, and infertility (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19958039','lexi-content-ref-12623765','lexi-content-ref-19113797','lexi-content-ref-15456328','lexi-content-ref-20187598','lexi-content-ref-30192094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19958039','lexi-content-ref-12623765','lexi-content-ref-19113797','lexi-content-ref-15456328','lexi-content-ref-20187598','lexi-content-ref-30192094'])">Ref</a></span>). Although long-term effects of antipsychotic-induced elevated prolactin levels have not been fully evaluated, some studies have also suggested a possible association between hyperprolactinemia and an increased risk for breast and/or pituitary tumors and osteopenia/osteoporosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12623765','lexi-content-ref-19113797','lexi-content-ref-11048906','lexi-content-ref-28360627','lexi-content-ref-20187598','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12623765','lexi-content-ref-19113797','lexi-content-ref-11048906','lexi-content-ref-28360627','lexi-content-ref-20187598','lexi-content-ref-28721057'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related (although a dose response is not consistently observed) and possibly time-related; antagonism of dopamine D<sub>2</sub> receptors in the tuberoinfundibular dopaminergic pathway which causes disinhibition of prolactin release resulting in hyperprolactinemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19958039','lexi-content-ref-11048906','lexi-content-ref-16282852','lexi-content-ref-20187598']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19958039','lexi-content-ref-11048906','lexi-content-ref-16282852','lexi-content-ref-20187598'])">Ref</a></span>). Haloperidol has been shown to have a strong D<sub>2</sub> receptor occupancy and antagonistic properties in the pituitary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20361897','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20361897','lexi-content-ref-28721057'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; onset is typically within a few days or weeks following initiation or a dosage increase and usually persists throughout treatment (although partial tolerance may develop). Onset may also arise after long-term stable use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19958039','lexi-content-ref-20187598']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19958039','lexi-content-ref-20187598'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Specific antipsychotic: Haloperidol is considered to be a prolactin-elevating antipsychotic with an intermediate to high risk for hyperprolactinemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19958039','lexi-content-ref-11048906','lexi-content-ref-28360627']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19958039','lexi-content-ref-11048906','lexi-content-ref-28360627'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19113797']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19113797'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (particularly those of reproductive age) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19958039','lexi-content-ref-19113797','lexi-content-ref-21346608']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19958039','lexi-content-ref-19113797','lexi-content-ref-21346608'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Younger patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19113797']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19113797'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Metabolic syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">All antipsychotics are associated with metabolic syndrome, which is comprised of significant <b>weight gain </b>(increase of ≥7% from baseline), <b>hyperglycemia</b>, diabetes mellitus, dyslipidemia, and <b>hypertension</b>. Although metabolic abnormalities are usually associated with second-generation (atypical) antipsychotics, the syndrome also occurs in varying degrees with the first-generation (typical) antipsychotics, including haloperidol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31524318','lexi-content-ref-19958039','lexi-content-ref-22009159','lexi-content-ref-19494785','lexi-content-ref-20187598','lexi-content-ref-17012695','lexi-content-ref-28721057','lexi-content-ref-26407790']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31524318','lexi-content-ref-19958039','lexi-content-ref-22009159','lexi-content-ref-19494785','lexi-content-ref-20187598','lexi-content-ref-17012695','lexi-content-ref-28721057','lexi-content-ref-26407790'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> The mechanism for metabolic abnormalities and weight gain is not entirely understood and is likely multifactorial. Multiple proposed mechanisms, including actions at serotonin, dopamine, histamine, and muscarinic receptors, with differing effects explained by differing affinity of antipsychotics at these receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731','lexi-content-ref-22009159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731','lexi-content-ref-22009159'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Weight gain: Varied; antipsychotic-induced weight gain usually occurs rapidly in the initial period following initiation, then gradually decreases and flattens over several months with patients continuing to gain weight in the long term (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Weight gain:</p>
<p style="text-indent:-2em;margin-left:8em;">• Family history of obesity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Parental BMI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Children and adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159','lexi-content-ref-15998156']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159','lexi-content-ref-15998156'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Rapid weight gain in the initial period: Younger age, lower baseline BMI, more robust response to antipsychotic and increase in appetite; rapid weight gain of &gt;5% in the first month has been observed as the best predictor for significant long-term weight gain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Duration of therapy (although weight gain plateaus, patients continue to gain weight over time) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Schizophrenia, regardless of medication, is associated with a higher prevalence of obesity compared to the general population due to components of the illness such as negative symptoms, sedentary lifestyles, unhealthy diets (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28861176']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28861176'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Specific antipsychotic: Haloperidol is usually associated with a low propensity for causing weight gain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19958039','lexi-content-ref-28883731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19958039','lexi-content-ref-28883731'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Lipid/glucose metabolism abnormalities:</p>
<p style="text-indent:-2em;margin-left:8em;">• Specific antipsychotic: Haloperidol is usually associated with low risk of causing lipid and/or glucose metabolism abnormalities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159','lexi-content-ref-19494785','lexi-content-ref-25082252']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159','lexi-content-ref-19494785','lexi-content-ref-25082252'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Mortality in older adults</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Older adults with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17548409','lexi-content-ref-17325327','lexi-content-ref-16234500']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17548409','lexi-content-ref-17325327','lexi-content-ref-16234500'])">Ref</a></span>). For haloperidol specifically, increased risk of mortality has also been observed with the cause of death varying and attributed to a number of causes including pneumonia, acute myocardial infarction, venous thromboembolism, stroke, hip fracture, and cardiac arrhythmias (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19138567','lexi-content-ref-25140533','lexi-content-ref-25786075','lexi-content-ref-29592958','lexi-content-ref-28721057','lexi-content-ref-27298071']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19138567','lexi-content-ref-25140533','lexi-content-ref-25786075','lexi-content-ref-29592958','lexi-content-ref-28721057','lexi-content-ref-27298071'])">Ref</a></span>). Of note, haloperidol is not approved for the treatment of dementia-related psychosis.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Unknown; possible mechanisms include arrhythmia, cardiac arrest, and extrapyramidal effects that may increase the risk of falls, aspirations, and pneumonia. In addition, haloperidol has been found to induce apoptosis and cause neurotoxicity, which also may play a role (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24016844']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24016844'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Antipsychotic class (a higher risk of increased mortality has been observed for first-generation antipsychotics, and haloperidol specifically, compared to second-generation antipsychotics) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25140533','lexi-content-ref-25786075','lexi-content-ref-16234500']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25140533','lexi-content-ref-25786075','lexi-content-ref-16234500'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher antipsychotic dosage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25140533','lexi-content-ref-22193526','lexi-content-ref-25786075']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25140533','lexi-content-ref-22193526','lexi-content-ref-25786075'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Dementia-related psychosis (eg, Lewy body dementia, Parkinson disease dementia)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neuroleptic malignant syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">All antipsychotics have been associated with <b>neuroleptic malignant syndrome</b> (NMS) in all ages. First-generation antipsychotic-associated NMS seems to occur at a higher frequency, severity, and lethality compared to second-generation antipsychotic-associated NMS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25578944','lexi-content-ref-28721057','lexi-content-ref-22626633']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25578944','lexi-content-ref-28721057','lexi-content-ref-22626633'])">Ref</a></span>). There are numerous reports of NMS occurring with haloperidol, either as monotherapy or in combination with other medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30375086','lexi-content-ref-19276778','lexi-content-ref-21172575','lexi-content-ref-6844982','lexi-content-ref-11866368','lexi-content-ref-19213967','lexi-content-ref-25183567','lexi-content-ref-24794843']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30375086','lexi-content-ref-19276778','lexi-content-ref-21172575','lexi-content-ref-6844982','lexi-content-ref-11866368','lexi-content-ref-19213967','lexi-content-ref-25183567','lexi-content-ref-24794843'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non-dose-related; idiosyncratic. Believed to be due to a reduction in CNS dopaminergic tone, along with the dysregulation of autonomic nervous system activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25578944','lexi-content-ref-24794843']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25578944','lexi-content-ref-24794843'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; in general, most patients develop NMS within 2 weeks of initiating an antipsychotic or a dosage increase, and in some patients, prodromal symptoms emerge within hours of initiation; once the syndrome starts, the full syndrome usually develops in 3 to 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17414689','lexi-content-ref-24794843']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17414689','lexi-content-ref-24794843'])">Ref</a></span>). However, there are many cases of NMS occurring months after stable antipsychotic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12766935']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12766935'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Antipsychotics in general:</p>
<p style="text-indent:-2em;margin-left:8em;">• Antipsychotic class: First-generation antipsychotics seem to have a higher risk of NMS compared to atypical antipsychotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19213967','lexi-content-ref-28721057','lexi-content-ref-18628446']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19213967','lexi-content-ref-28721057','lexi-content-ref-18628446'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Specific antipsychotic: Potent agents such as haloperidol are thought to confer the greatest risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23983836']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23983836'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Males (twice as likely to develop NMS compared to females) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9735957','lexi-content-ref-22626633']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9735957','lexi-content-ref-22626633'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Dehydration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034','lexi-content-ref-19213967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034','lexi-content-ref-19213967'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• High-dose antipsychotic treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant lithium or benzodiazepine (potential risk factors) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Catatonia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Polypharmacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Pharmacokinetic interactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• IM administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19213967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19213967'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Rapid dosage escalation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19213967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19213967'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Psychomotor agitation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19213967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19213967'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">QTc prolongation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Haloperidol has been associated with a <b>prolonged QT interval on ECG, torsades de pointes</b> (TdP), and sudden cardiac death in all ages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11866368','lexi-content-ref-25183567','lexi-content-ref-24898718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11866368','lexi-content-ref-25183567','lexi-content-ref-24898718'])">Ref</a></span>). In general, intravenous haloperidol is associated with a higher risk of QTc prolongation than the oral and IM route; however, the higher risk attributed to intravenous haloperidol has been questioned and recent evidence suggests it have been confounded by its use in medically ill patients with concomitant risk factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20210726','lexi-content-ref-23295003','lexi-content-ref-29275963','lexi-content-ref-32345400','lexi-content-ref-32614955','lexi-content-ref-14709949','lexi-content-ref-15342619','lexi-content-ref-14585064','lexi-content-ref-24967672','lexi-content-ref-20394022','lexi-content-ref-15226162','lexi-content-ref-22114630']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20210726','lexi-content-ref-23295003','lexi-content-ref-29275963','lexi-content-ref-32345400','lexi-content-ref-32614955','lexi-content-ref-14709949','lexi-content-ref-15342619','lexi-content-ref-14585064','lexi-content-ref-24967672','lexi-content-ref-20394022','lexi-content-ref-15226162','lexi-content-ref-22114630'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Haloperidol prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current (Ikr) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20210726','lexi-content-ref-23295003','lexi-content-ref-32345400','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20210726','lexi-content-ref-23295003','lexi-content-ref-32345400','lexi-content-ref-32929996'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Drug-induced QTc prolongation/TdP (in general):</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Age &gt;65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Structural heart disease (eg, history of myocardial infarction or heart failure with a reduced ejection fraction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of drug-induced TdP (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Genetic defects of cardiac ion channels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Congenital long QT syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Baseline QTc interval prolongation (eg, &gt;500 msec) or lengthening of the QTc by ≥60 msec (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Electrolyte disturbances (eg, hypokalemia, hypocalcemia, hypomagnesemia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Bradycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hepatic impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032','lexi-content-ref-24803473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032','lexi-content-ref-24803473'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Co-administration of multiple medications (≥2) that prolong the QT interval or increase drug interactions that increase serum drug concentrations of QTc prolonging medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Substance use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20210726']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20210726'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Seizures</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Haloperidol may lower the seizure threshold and cause <b>seizures</b> rarely, although evidence is weak and limited (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26242478','lexi-content-ref-11866368','lexi-content-ref-23146619','lexi-content-ref-11888352','lexi-content-ref-27249081']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26242478','lexi-content-ref-11866368','lexi-content-ref-23146619','lexi-content-ref-11888352','lexi-content-ref-27249081'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Mechanism is unknown although a role of dopamine has been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11888352','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11888352','lexi-content-ref-28721057'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>
<i>: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Antipsychotics in general:</p>
<p style="text-indent:-2em;margin-left:8em;">• History of seizure activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12973403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12973403'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concurrent use of drugs that lower seizure threshold (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12973403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12973403'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Rapid dose titration or sudden increase in dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12973403','lexi-content-ref-11888352']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12973403','lexi-content-ref-11888352'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Slow drug metabolism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12973403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12973403'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Metabolic factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12973403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12973403'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Drug-drug interactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12973403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12973403'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Organic brain disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20187598']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20187598'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Sexual dysfunction</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antipsychotics have been associated with <b>sexual disorders</b> in both males and females. Antipsychotic treatment has been associated with effects on all phases of sexual activity (libido, arousal, and orgasm); however, many patients with schizophrenia experience more frequent sexual dysfunction, with or without antipsychotic treatment. The following adverse reactions have been observed with haloperidol: <b>Decreased libido</b>,<b> erectile dysfunction, </b>and <b>orgasm abnormal </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12623765','lexi-content-ref-23737244','lexi-content-ref-21191308','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12623765','lexi-content-ref-23737244','lexi-content-ref-21191308','lexi-content-ref-28721057'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Antipsychotic-induced sexual dysfunction has been attributed to many potential mechanisms, including dopamine receptor antagonism, dopamine D<sub>2 </sub>receptor antagonism in the hypothalamic infundibular system causing hyperprolactinemia, histamine receptor antagonism, cholinergic receptor antagonism, and alpha-adrenergic receptor antagonism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23737244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23737244'])">Ref</a></span>). Of note, haloperidol is associated with a high propensity for elevating prolactin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19958039','lexi-content-ref-23737244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19958039','lexi-content-ref-23737244'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Hyperprolactinemia (although a correlation with sexual dysfunction has been observed, a relationship has not been confirmed) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23737244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23737244'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Schizophrenia (the prevalence of antipsychotic-induced sexual dysfunction in patients with schizophrenia is high [~50% to 60% compared with 31% of men in the general population]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22533871']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22533871'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Specific antipsychotic: Some studies have observed a high prevalence of sexual dysfunction with haloperidol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12623765','lexi-content-ref-23737244','lexi-content-ref-21191308']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12623765','lexi-content-ref-23737244','lexi-content-ref-21191308'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Temperature dysregulation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antipsychotics may impair the body's ability to regulate core body temperature, which may cause a potentially life-threatening heat stroke during predisposing conditions such a heat wave or strenuous exercise. There are also several case reports of potentially life-threatening <b>hypothermia </b>associated with haloperidol use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9712220','lexi-content-ref-31306860','lexi-content-ref-11199936','lexi-content-ref-7891424','lexi-content-ref-17401555','lexi-content-ref-28936184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9712220','lexi-content-ref-31306860','lexi-content-ref-11199936','lexi-content-ref-7891424','lexi-content-ref-17401555','lexi-content-ref-28936184'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Non-dose-related; idiosyncratic. Exact mechanism is unknown; however, body temperature is regulated by the hypothalamus with involvement of the dopamine, serotonin, and norepinephrine neurotransmitters. D<sub>2 </sub>antagonism may cause an increase in body temperature, while 5-HT<sub>2A</sub> (serotonin) receptor antagonism may cause a decrease in body temperature. In addition, antagonism of peripheral alpha-adrenergic receptors has also been suggested as a factor in the hypothermic effect, by inhibiting peripheral responses to cooling (vasoconstriction and shivering) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11199936','lexi-content-ref-17401555','lexi-content-ref-28936184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11199936','lexi-content-ref-17401555','lexi-content-ref-28936184'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Hypothermia: Varied; antipsychotic-induced hypothermia cases indicate a typical onset in the period shortly after initiation of therapy or a dosage increase (first 7 to 10 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28936184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28936184'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Heat stroke:</p>
<p style="text-indent:-2em;margin-left:8em;">• Psychiatric illness (regardless of medication use) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9712220','lexi-content-ref-17698676','lexi-content-ref-18941580']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9712220','lexi-content-ref-17698676','lexi-content-ref-18941580'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Dehydration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16174785','lexi-content-ref-12190212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16174785','lexi-content-ref-12190212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Strenuous exercise (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16174785','lexi-content-ref-12190212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16174785','lexi-content-ref-12190212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Heat exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3979264','lexi-content-ref-16174785','lexi-content-ref-12190212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3979264','lexi-content-ref-16174785','lexi-content-ref-12190212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant medication possessing anticholinergic effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3979264','lexi-content-ref-16174785','lexi-content-ref-12190212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3979264','lexi-content-ref-16174785','lexi-content-ref-12190212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Hypothermia:</p>
<p style="text-indent:-2em;margin-left:8em;">• In general, predisposing risk factors include: Older adults, cerebrovascular accident, preexisting brain damage, hypothyroidism, malnutrition, shock, sepsis, adrenal insufficiency, diabetes, disability, burns, exfoliative dermatitis benzodiazepine use, polypharmacy, alcohol intoxication, immobility, kidney or liver failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31306860','lexi-content-ref-24688758','lexi-content-ref-28936184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31306860','lexi-content-ref-24688758','lexi-content-ref-28936184'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Schizophrenia (regardless of antipsychotic use) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17401555']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17401555'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F178516"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Nervous system: Extrapyramidal reaction, parkinsonism</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, constipation, sialorrhea, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Akathisia, akinesia, drowsiness, dystonia, headache, hypertonia, tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Bradykinesia, hyperkinetic muscle activity</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Oculogyric crisis</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension, orthostatic hypotension, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acneiform eruption</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Heavy menstrual bleeding, weight gain</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysmenorrhea, mastalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cogwheel rigidity, dizziness, mask-like face, restlessness, sedated state, trismus</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Dyskinesia, hypokinesia, muscle rigidity, muscle twitching, torticollis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, nystagmus disorder</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia, hyponatremia, increased libido, menstrual disease</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, diarrhea, dyspepsia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Breast engorgement, impotence, lactation</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety, euphoria, lethargy, psychotic symptoms (exacerbation), vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Cataract, retinopathy, visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Increased depth of respiration</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema, extrasystoles (Mehta 1979), hypertension, prolonged QT interval on ECG (Douglas 2000), torsades de pointes (O’Brien 1999, Tisdale 2020), ventricular arrhythmia (Mehta 1979), ventricular fibrillation (Douglas 2000), ventricular tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, exfoliative dermatitis, hyperhidrosis, maculopapular rash, pruritus, skin photosensitivity, skin rash, urticaria (Balai 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Amenorrhea (Bobes 2003), decreased libido (Bobes 2003), galactorrhea not associated with childbirth (Bobes 2003), gynecomastia (Bobes 2003), heatstroke, hyperammonemia, hyperprolactinemia (Crawford 1997), hypoglycemia (Couto 2019), SIADH, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholestasis, dysphagia (Dziewas 2007), nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Erectile dysfunction (Bobes 2003), orgasm abnormal (Bobes 2003), priapism, sexual disorder (Bobes 2003), urinary retention</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Jurivich 1987), anemia, leukocytosis (Youniss 2021), leukopenia (Cutler 1979), lymphocytosis with monocytosis, neutropenia (Şahan 2019), pancytopenia (Remelli 2020), thrombocytopenia (Remelli 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Acute hepatic failure, hepatic insufficiency, hepatitis, jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema (Masiran 2017, Muzyk 2012), facial edema (Balai 2017), hypersensitivity angiitis (Lee 1999), hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Abscess at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation, confusion, depression, dystonic reaction (laryngeal) (Christodoulou 2005), hyperthermia (Bach 1985), hypothermia (Harada 1994), insomnia, motor dysfunction, neonatal withdrawal (Sexson 1989), neuroleptic malignant syndrome (Seitz 2009), opisthotonus, seizure (Bloechlinger 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Laryngospasm, rhabdomyolysis (Marsh 1995), tardive dyskinesia (Correll 2004), tardive dystonia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchopneumonia, bronchospasm (Sethna 1991), dyspnea, exacerbation of asthma (can be severe) (Kuo 2022), laryngeal edema, pulmonary aspiration (Dziewas 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (Youniss 2021)</p></div>
<div class="block coi drugH1Div" id="F178532"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to haloperidol or any component of the formulation; Parkinson disease; severe CNS depression; coma; dementia with Lewy bodies.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling</i>: Additional contraindications (not in US labeling): Significant depressive states; previous spastic diseases; young children; patients of childbearing potential; breastfeeding; IV administration (IM injection).</p></div>
<div class="block war drugH1Div" id="F178513"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Falls: May increase the risk for falls due to somnolence, orthostatic hypotension, and motor or sensory instability.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with severe cardiovascular disease because of the possibility of transient hypotension and/or precipitation of angina pain.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bipolar disorder: Use with caution in patients with bipolar disorder; when used to control mania, there may be a rapid mood swing to depression. Haloperidol does not possess antidepressant effects (Cipriani 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use with caution in patients with myasthenia gravis; may exacerbate condition (Mehrizi 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">• Parkinson disease: Haloperidol is contraindicated in patients with Parkinson disease; these patients are reported to be more sensitive to antipsychotic medications and use may result in severe extrapyramidal symptoms, confusion, sedation, and falls.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid dysfunction: Avoid in thyrotoxicosis; severe neurotoxicity (rigidity, inability to walk or talk) may occur with use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sesame oil: Some decanoate products may contain sesame oil.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: When discontinuing antipsychotic therapy, gradually taper antipsychotics to avoid physical withdrawal symptoms and rebound symptoms (APA [Keepers 2020]; WFSBP [Hasan 2012]). Withdrawal symptoms may include agitation, alternating feelings of warmth and cold, anxiety, diaphoresis, dyskinesia, GI symptoms, insomnia, irritability, myalgia, paresthesia, psychosis, restlessness, rhinorrhea, tremor, and vertigo (Lambert 2007; Moncrieff 2020). The risk of withdrawal symptoms is highest following abrupt discontinuation of highly anticholinergic or dopaminergic antipsychotics (Cerovecki 2013). Patients with chronic symptoms, repeated relapses, and clear diagnostic features of schizophrenia are at risk for poor outcomes if medications are discontinued (APA [Keepers 2020]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Parenteral administration: Hypotension may occur, particularly with parenteral administration. Although the short-acting form (lactate) is used clinically intravenously, the IV use of the injection is not an FDA-approved route of administration; the decanoate form should never be administered intravenously.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878480"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">For the management of delirium in pediatric patients, intravenous haloperidol has been widely studied for efficacy and has been frequently used due to lower sedative effects and rapid onset of action; however, its use is associated with adverse effects (Harrison 2006; Slooff 2014; Turkel 2014). Newer atypical antipsychotics have shown similar efficacy with less adverse effects and are being utilized more frequently. Intravenous haloperidol for delirium may be considered in patients that are unresponsive to an atypical agent or who require intravenous therapy; ECG monitoring could be considered (Turkel 2014).</p></div>
<div class="block foc drugH1Div" id="F178524"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Concentrate, Oral, as lactate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg/mL (5 mL, 15 mL, 120 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intramuscular, as decanoate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Haldol Decanoate: 50 mg/mL (1 mL); 100 mg/mL (1 mL) [contains benzyl alcohol, sesame oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/mL (1 mL, 5 mL); 100 mg/mL (1 mL, 5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as lactate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Haldol: 5 mg/mL (1 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg/mL (1 mL, 10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as lactate [strength expressed as base, preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg, 1 mg, 2 mg, 5 mg, 10 mg, 20 mg</p></div>
<div class="block geq drugH1Div" id="F178509"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F178534"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Concentrate</b> (Haloperidol Lactate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg/mL (per mL): $0.84 - $0.88</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Haldol Decanoate Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/mL (per mL): $104.49</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/mL (per mL): $199.19</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Haloperidol Decanoate Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/mL (per mL): $7.56 - $33.70</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/mL (per mL): $15.12 - $61.78</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Haloperidol Lactate Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/mL (per mL): $0.48 - $7.19</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Haloperidol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $0.33 - $0.89</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $0.46 - $1.07</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $0.63 - $1.25</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.69 - $1.29</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.53 - $2.01</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $1.56 - $3.62</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867100"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Concentrate, Oral, as lactate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg/mL ([DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg/mL (1 mL, 10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intramuscular, as decanoate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/mL (1 mL, 5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as lactate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg, 1 mg, 2 mg, 5 mg, 10 mg, 20 mg [DSC]</p></div>
<div class="block adm drugH1Div" id="F178529"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Injection oil (decanoate): The decanoate injectable formulation should be administered IM only, <b>do not administer decanoate IV.</b> A 21-gauge needle is recommended. The maximum volume per injection site should not exceed 3 mL. Z-track injection techniques are recommended to limit leakage after injections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22250654','lexi-content-ref-23905227','lexi-content-ref-16822092']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22250654','lexi-content-ref-23905227','lexi-content-ref-16822092'])">Ref</a></span>). Experts recommend administering in the gluteal muscle by deep IM injection, however haloperidol by deltoid injection has been studied with positive results (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22250654','lexi-content-ref-23905227','lexi-content-ref-24846035','lexi-content-ref-12485307','lexi-content-ref-22450010']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22250654','lexi-content-ref-23905227','lexi-content-ref-24846035','lexi-content-ref-12485307','lexi-content-ref-22450010'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Injection solution (lactate): The lactate injectable formulation may be administered IM or IV (off-label route). Rate of IV administration not well defined; rates of a maximum of 5 mg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-822989','lexi-content-ref-380367']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-822989','lexi-content-ref-380367'])">Ref</a></span>) and 0.125 mg/kg over 1 to 2 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6831826','lexi-content-ref-4008674']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6831826','lexi-content-ref-4008674'])">Ref</a></span>) have been reported. <b>Note:</b> IV administration has been associated with QT prolongation and the manufacturer recommends ECG monitoring for QT prolongation and arrhythmias. Consult individual institutional policies and procedures prior to administration. Subcutaneous administration has also been reported (usually in the palliative care setting), either as intermittent administration or as a continuous subcutaneous infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19093700','lexi-content-ref-20619214','lexi-content-ref-7544674']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19093700','lexi-content-ref-20619214','lexi-content-ref-7544674'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52612967"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer with food or milk to decrease GI distress. Avoid skin contact with oral suspension or solution; may cause contact dermatitis.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Lactate (immediate release): May be administered undiluted IM.</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Infusion or IVPB: Lactate (immediate release): May be administered undiluted (5 mg/mL), or diluted in D5W. Rate of IV administration is not well defined but should be slow; in pediatric delirium patients, loading doses have been administered over 30 to 45 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15782087','lexi-content-ref-17457571']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15782087','lexi-content-ref-17457571'])">Ref</a></span>); in adults, rates of a maximum of 5 mg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-822989','lexi-content-ref-380367']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-822989','lexi-content-ref-380367'])">Ref</a></span>) and 0.125 mg/kg (in 10 mL NS) over 1 to 2 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6831826','lexi-content-ref-4008674']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6831826','lexi-content-ref-4008674'])">Ref</a></span>) have been reported. <b>Note:</b> The administration of IV haloperidol is associated with QT prolongation and torsades de pointes; in adults without concomitant risk factors, this effect is dose dependent and was reported with cumulative IV doses ≥2 mg; in all patients, increased monitoring is necessary at baseline and during administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20142454','lexi-content-ref-20394022','lexi-content-ref-23639666']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20142454','lexi-content-ref-20394022','lexi-content-ref-23639666'])">Ref</a></span>). Consult individual institutional policies and procedures prior to administration.</p></div>
<div class="block use drugH1Div" id="F178528"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Behavioral disorders, nonpsychotic (tablet, concentrate):</b> Treatment of severe behavioral problems in children with combative, explosive hyperexcitability that cannot be accounted for by immediate provocation. Reserve for use in these children only after failure to respond to psychotherapy or medications other than antipsychotics.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperactivity (tablet, concentrate):</b> Short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggression, mood lability, or poor frustration tolerance. Reserve for use in these children only after failure to respond to psychotherapy or medications other than antipsychotics.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Schizophrenia: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM lactate:</b> Treatment of schizophrenia.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM decanoate:</b> Treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Tablet, concentrate:</b> Treatment of manifestations of psychotic disorders such as schizophrenia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Tourette syndrome, management of tics (tablet, concentrate):</b> Control of tics and vocal utterances in Tourette syndrome in adults and children.</p></div>
<div class="block off-label drugH1Div" id="F25474798"><span class="drugH1">Use: Off-Label: Adult</span><p>Agitation/Aggression (severe, acute) associated with psychiatric disorders (eg, schizophrenia), substance intoxication, or other organic causes; Bipolar disorder (acute mania, episodes with mixed features or acute hypomania); Chemotherapy-induced breakthrough nausea and vomiting; Delirium, hyperactive (treatment); Nausea and vomiting in advanced or terminal illness (palliative care); Postoperative nausea and vomiting, prevention, moderate- to high-risk patients</p></div>
<div class="block mst drugH1Div" id="F178612"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Haldol may be confused with Halcion, Halog, Stadol</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Antipsychotics are identified in the Beers Criteria as potentially inappropriate medications to be avoided in patients 65 years and older due to an increased risk of stroke and a greater rate of cognitive decline and mortality in patients with dementia. Evidence also suggests there may be an increased risk of mortality with use independent of dementia. Avoid antipsychotics for behavioral problems associated with dementia or delirium unless alternative nonpharmacologic therapies have failed and patient may harm self or others. In addition, antipsychotics should be used with caution in older adults due to their potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults. Use of antipsychotics may be appropriate for labeled indications, including schizophrenia, bipolar disorder, Parkinson disease psychosis, adjunctive therapy in major depressive disorder, or for short-term use as an antiemetic (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Dopamine antagonists, when used in pediatric patients &lt;18 years of age, are identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list; use should be avoided in infants and used with caution in children and adolescents due to risk of acute dystonia (dyskinesia), and with intravenous administration an increased risk of respiratory depression, extravasation, and death (strong recommendation; moderate quality of evidence) (PPA [Meyers 2020]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Haldol [US and multiple international markets] may be confused with Halotestin brand name for fluoxymesterone [Great Britain]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F178598"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2D6 (major), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F178518"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents With Seizure Threshold Lowering Potential: May enhance the adverse/toxic effect of Haloperidol. Specifically, the risk of seizures may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifampridine: Agents With Seizure Threshold Lowering Potential may enhance the neuroexcitatory and/or seizure-potentiating effect of Amifampridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: May enhance the QTc-prolonging effect of Haloperidol. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the QTc-prolonging effect of Haloperidol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anti-Parkinson Agents (Dopamine Agonist): May diminish the therapeutic effect of Antipsychotic Agents (First Generation [Typical]). Antipsychotic Agents (First Generation [Typical]) may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Management: Avoid concomitant therapy if possible. If antipsychotic use is necessary, consider using atypical antipsychotics such as clozapine, quetiapine, or ziprasidone at lower initial doses, or a non-dopamine antagonist (eg, pimavanserin).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole Lauroxil. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asenapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Asenapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Benperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Brexpiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabergoline: May diminish the therapeutic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: May decrease the serum concentration of Haloperidol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Cariprazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Anticholinergic Agents may enhance the anticholinergic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clothiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Clothiapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Moderate): May increase the serum concentration of Haloperidol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Strong): May increase the serum concentration of Haloperidol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Haloperidol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Haloperidol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: Haloperidol may enhance the QTc-prolonging effect of Dabrafenib.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deutetrabenazine: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for akathisia, parkinsonism, or neuroleptic malignant syndrome may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: Haloperidol may enhance the QTc-prolonging effect of Domperidone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Donepezil: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of DroPERidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May enhance the QTc-prolonging effect of Haloperidol. Encorafenib may decrease the serum concentration of Haloperidol. Management: Monitor for QTc interval prolongation, ventricular arrhythmias, and reduced haloperidol concentrations and efficacy when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Systemic): Haloperidol may diminish the vasoconstricting effect of EPINEPHrine (Systemic).  Management: Consider alternatives to this combination and monitor for reduced epinephrine efficacy, and possible paradoxical effects (ie, hypotension), when combined. Use of alternative vasopressor agents (eg, phenylephrine, metaraminol, norepinephrine) is preferred.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: Haloperidol may enhance the QTc-prolonging effect of Fluorouracil Products.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flupentixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Flupentixol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FluPHENAZine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of FluPHENAZine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FluvoxaMINE: May increase the serum concentration of Haloperidol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Galantamine: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Systemic): May decrease the serum concentration of Haloperidol. Management: Consider avoiding concurrent use of glycopyrrolate and haloperidol.Monitor patients closely for signs/symptoms of reduced clinical response to haloperidol if concurrent use with glycopyrrolate is required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: Antipsychotic Agents may diminish the therapeutic effect of Guanethidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Homochlorcyclizine: May enhance the anticholinergic effect of Haloperidol. Homochlorcyclizine may enhance the CNS depressant effect of Haloperidol. Homochlorcyclizine may increase the serum concentration of Haloperidol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Huperzine A: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iloperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iloperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indomethacin: May enhance the CNS depressant effect of Haloperidol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: May enhance the QTc-prolonging effect of QT-prolonging CYP3A4 Substrates. Management: Do not use lefamulin tablets with QT-prolonging CYP3A4 substrates. Lefamulin prescribing information lists this combination as contraindicated.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging CYP3A4 Substrates may enhance the QTc-prolonging effect of Levoketoconazole. Levoketoconazole may increase the serum concentration of QT-prolonging CYP3A4 Substrates. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: May enhance the neurotoxic effect of Antipsychotic Agents. Lithium may decrease the serum concentration of Antipsychotic Agents. Specifically noted with chlorpromazine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loxapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Loxapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lumateperone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lurasidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mequitazine: Antipsychotic Agents may enhance the arrhythmogenic effect of Mequitazine.  Management: Consider alternatives to one of these agents when possible.  While this combination is not specifically contraindicated, mequitazine labeling describes this combination as discouraged.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: Haloperidol may enhance the CNS depressant effect of Methadone. Haloperidol may enhance the QTc-prolonging effect of Methadone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation or those taking IV haloperidol may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methyldopa: Haloperidol may enhance the adverse/toxic effect of Methyldopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for extrapyramidal symptoms and excessive sedation may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molindone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Molindone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of OLANZapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: May enhance the QTc-prolonging effect of Haloperidol. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paliperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Paliperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentamidine (Systemic): Haloperidol may enhance the QTc-prolonging effect of Pentamidine (Systemic).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Periciazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Periciazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perphenazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Perphenazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: May enhance the QTc-prolonging effect of Haloperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pipamperone [INT]: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Pipamperone [INT]. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: Antipsychotic Agents may diminish the therapeutic effect of Piribedil. Piribedil may diminish the therapeutic effect of Antipsychotic Agents.  Management: Use of piribedil with antiemetic neuroleptics is contraindicated, and use with antipsychotic neuroleptics, except for clozapine, is not recommended.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Polyethylene Glycol-Electrolyte Solution. Specifically, the risk of seizure may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Posaconazole: May increase the serum concentration of QT-prolonging CYP3A4 Substrates. Such increases may lead to a greater risk for proarrhythmic effects and other similar toxicities.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prochlorperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Prochlorperazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Promazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promethazine: May enhance the anticholinergic effect of Haloperidol. Promethazine may enhance the CNS depressant effect of Haloperidol. Promethazine may increase the serum concentration of Haloperidol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Indeterminate Risk - Avoid): May enhance the QTc-prolonging effect of Haloperidol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Indeterminate Risk - Caution): May enhance the QTc-prolonging effect of Haloperidol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antidepressants (Moderate Risk): May enhance the QTc-prolonging effect of Haloperidol. Haloperidol may enhance the serotonergic effect of QT-prolonging Antidepressants (Moderate Risk). This could result in serotonin syndrome. Management: Monitor for QTc interval prolongation, ventricular arrhythmias, and serotonin syndrome/serotonin toxicity (SS/ST) or NMS when these agents are combined. Patients with additional risk factors for QTc prolongation or SS/ST may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antipsychotics (Moderate Risk): May enhance the QTc-prolonging effect of Haloperidol. Management: Monitor for QTc interval prolongation, ventricular arrhythmias, and serotonin syndrome/serotonin toxicity (SS/ST) or NMS when these agents are combined. Patients with additional risk factors for QTc prolongation or SS/ST may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IA Antiarrhythmics (Highest Risk): May enhance the QTc-prolonging effect of Haloperidol. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IC Antiarrhythmics (Moderate Risk): May enhance the QTc-prolonging effect of Haloperidol. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class III Antiarrhythmics (Highest Risk): May enhance the QTc-prolonging effect of Haloperidol. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-Prolonging Inhalational Anesthetics (Moderate Risk): Haloperidol may enhance the QTc-prolonging effect of QT-Prolonging Inhalational Anesthetics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Highest Risk): May enhance the QTc-prolonging effect of Haloperidol. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of Haloperidol. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Miscellaneous Agents (Highest Risk): May enhance the QTc-prolonging effect of Haloperidol. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Miscellaneous Agents (Moderate Risk): May enhance the QTc-prolonging effect of Haloperidol. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of Haloperidol. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Quinolone Antibiotics (Moderate Risk): Haloperidol may enhance the QTc-prolonging effect of QT-prolonging Quinolone Antibiotics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk): Haloperidol may enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk). QT-prolonging Strong CYP3A4 Inhibitors (Highest Risk) may increase the serum concentration of Haloperidol.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk): Haloperidol may enhance the QTc-prolonging effect of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Haloperidol.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of QUEtiapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: Antipsychotic Agents may diminish the therapeutic effect of Quinagolide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinidine (Non-Therapeutic): May enhance the QTc-prolonging effect of QT-prolonging CYP2D6 Substrates. Quinidine (Non-Therapeutic) may increase the serum concentration of QT-prolonging CYP2D6 Substrates.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of RisperiDONE. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: May enhance the QTc-prolonging effect of Haloperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk): May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonergic agents may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sertindole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure or loss of consciousness may be increased in patients with significant sodium phosphate-induced fluid or electrolyte abnormalities. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulpiride: Antipsychotic Agents may enhance the adverse/toxic effect of Sulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for NMS and extrapyramidal symptoms may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thioridazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiothixene: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thiothixene. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tobacco (Smoked): May decrease the serum concentration of Haloperidol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trifluoperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Trifluoperazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triptorelin: Hyperprolactinemic Agents may diminish the therapeutic effect of Triptorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urea Cycle Disorder Agents: Haloperidol may diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically, Haloperidol may increase plasma ammonia concentrations and thereby increase the doses of Urea Cycle Disorder Agents needed to maintain concentrations in the target range. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vasopressin: Drugs Suspected of Causing SIADH may enhance the therapeutic effect of Vasopressin. Specifically, the pressor and antidiuretic effects of vasopressin may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuclopenthixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Zuclopenthixol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F55211822"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Haloperidol may increase prolactin serum concentrations, leading to decreased fertility in males and females (Drobnis 2017; Larsen 2015). When antipsychotic treatment is initiated for the first time in a patient planning to become pregnant, an agent other than haloperidol may be preferred (Larsen 2015).</p></div>
<div class="block pri drugH1Div" id="F10869024"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Haloperidol crosses the placenta in humans (Newport 2007). Although haloperidol has not been found to be a major human teratogen, an association with limb malformations following first trimester exposure in humans cannot be ruled out (ACOG 2008; Diav-Citrin 2005). Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms) and withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization. If needed, the minimum effective maternal dose should be used in order to decrease the risk of EPS (ACOG 2008).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of haloperidol may be altered. If treatment with haloperidol is required during pregnancy, regular therapeutic drug monitoring (eg, every 3 months) is recommended (Larsen 2015; Schoretsanitis 2020; Westin 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Haloperidol is preferred when a first-generation antipsychotic is needed in pregnant patients. If needed, the minimum effective maternal dose should be used in order to decrease the risk of extrapyramidal symptoms (ACOG 2008; Raffi 2019; WFSBP [Hasan 2015]).</p></div>
<div class="block brc drugH1Div" id="F178535"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol has been detected in the plasma and urine of breastfeeding infants (Whalley 1981; Yoshida 1999). Adverse events have been reported in some infants exposed to haloperidol via breast milk (Larsen 2015; Uguz 2019). Gynecomastia and galactorrhea are known side effects with the use of haloperidol. Breastfeeding is not recommended by the manufacturer. Some guidelines do not recommend initiating haloperidol in patients who are breastfeeding (Larsen 2015). Other guidelines note that if a first-generation antipsychotic is required, haloperidol is preferred; infants should be monitored for adverse events (WFSBP [Hasan 2015]).</p></div>
<div class="block mop drugH1Div" id="F178522"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Mental status; vital signs (as clinically indicated); ECG (as clinically indicated and with off-label intravenous administration); weight, height, BMI, waist circumference (baseline; at every visit for the first 6 months; quarterly with stable antipsychotic dose); CBC (as clinically indicated; monitor frequently during the first few months of therapy in patients with preexisting low WBC or history of drug-induced leukopenia/neutropenia); electrolytes and liver function (annually and as clinically indicated); fasting plasma glucose level/ HbA<sub>1c</sub> (baseline, then yearly; in patients with diabetes risk factors or if gaining weight repeat 4 months after starting antipsychotic, then yearly); lipid panel (baseline; repeat every 2 years if LDL level is normal; repeat every 6 months if LDL level is &gt;130 mg/dL); changes in menstruation, libido, development of galactorrhea, erectile and ejaculatory function (at each visit for the first 12 weeks after the antipsychotic is initiated or until the dose is stable, then yearly); abnormal involuntary movements or parkinsonian signs (baseline; repeat weekly until dose stabilized for at least 2 weeks after introduction and for 2 weeks after any significant dose increase); tardive dyskinesia (every 6 months; high-risk patients every 3 months); visual changes (inquire yearly); ocular examination (yearly in patients &gt;40 years; every 2 years in younger patients) (ADA 2004; Lehman 2004; Marder 2004); fall risk (baseline and periodically during treatment in patients with diseases or on medications that may also increase fall risk); signs and symptoms of NMS (mental status changes, fever, muscle rigidity, and/or autonomic instability).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Additional monitoring parameters with IV administration: </i>ECG (prior to administration and regularly [eg, daily] during administration to detect emerging QTc interval prolongation; consider continuous ECG, especially if patient has risk factors for QTc prolongation, the baseline ECG reveals a prolonged QTc, or cumulative doses of ≥2 mg are needed) (Drew 2010) some experts recommend continuous cardiac monitoring during administration and for 2 to 3 hours after administration (Jibson 2019); serum electrolytes (especially potassium and magnesium, prior to administration and throughout therapy).</p></div>
<div class="block rer drugH1Div" id="F178525"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Schizophrenia:</p>
<p style="text-indent:-2em;margin-left:4em;">Timing of serum samples: Draw trough just before next dose (Hiemke 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">Therapeutic reference range: 1 to 10 ng/mL (SI: 2.66 to 26.6 nmol/L) (Hiemke 2018). <b>Note: </b>Dosing should be based on therapeutic response as opposed to serum concentrations; however, therapeutic drug monitoring can be used to confirm adherence (APA [Keepers 2020]).</p>
<p style="text-indent:-2em;margin-left:4em;">Laboratory alert level: Variable; levels ranging from 15 ng/mL (SI: 39.9 nmol/L) to 50 ng/mL (SI: 133 nmol/L) have been identified as supratherapeutic and resulting in toxicity (Darby 1995; Hiemke 2018).</p></div>
<div class="block pha drugH1Div" id="F178512"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Haloperidol is a butyrophenone antipsychotic that nonselectively blocks postsynaptic dopaminergic D<sub>2</sub> receptors in the brain (Richelson 1999; Risch 1996).</p></div>
<div class="block phk drugH1Div" id="F178531"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Lactate:</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Agitation: Initial effects within 15 minutes with mean time to sedation 24.8 to 28.3 minutes (Isenberg 2015; Klein 2018; Nobay 2004).</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Sedation: 3 to 20 minutes (Jacobi 2002); Peak effect: Sedation: ~30 minutes (Forsman 1976; Jacobi 2002; Magliozzi 1985).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Bipolar disorder, acute mania: Oral and IR injection: Initial effects may be observed within days of treatment with continued improvements over 1 to 2 weeks (Goikolea 2013; Tohen 2000; Welten 2016).</p>
<p style="text-indent:-2em;margin-left:6em;">Schizophrenia: Oral: Initial effects may be observed within 1 to 2 weeks of treatment with continued improvements through 4 to 6 weeks (Agid 2003; Levine 2010).</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Lactate (dose dependent):</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Sedation: Mean: 126.5 minutes (Nobay 2004).</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Sedation: Reported range: 3 to 24 hours (Magliozzi 1985).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution:</p>
<p style="text-indent:-2em;margin-left:4em;">IV: V<sub>z</sub>: 9.5 to 21.7 L/kg (Kudo 1999).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: V<sub>z</sub>/F: 52.6 ± 14.5 L/kg (Kudo 1999).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 88.4% to 92.5% (Kudo 1999).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic: 50% to 60% glucuronidation (inactive); 23% CYP3A4-mediated reduction to inactive metabolites (some back-oxidation to haloperidol); and 20% to 30% CYP3A4-mediated N-dealkylation, including minor oxidation pathway to toxic pyridinium derivative (Kudo 1999).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: 60% to 70% (Kudo 1999).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Decanoate: 21 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Lactate:</p>
<p style="text-indent:-2em;margin-left:6em;">IM: 20 hours (Kudo 1999).</p>
<p style="text-indent:-2em;margin-left:6em;">IV: 14 to 26 hours (Kudo 1999).</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: 14 to 37 hours (Kudo 1999).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum:</p>
<p style="text-indent:-2em;margin-left:4em;">Decanoate: 6 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Lactate:</p>
<p style="text-indent:-2em;margin-left:6em;">IM: 20 minutes (Kudo 1999).</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: 2 to 6 hours (Kudo 1999).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (30%, 1% as unchanged drug) (Kudo 1999).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F178536"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Haldol | Serenace</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Chaupidol | Enabran | Haloperidol decanoato | Haloperidol denver farma | Haloperidol Drawer | Haloperidol vannier | Halopidol | Halopidol decanoato | Halozen | Limerix | Neupram</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Haldol</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Haldol deconate | Haloperidol | Serenace</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Halop | Peldol | Peridol | Perigen | Perol | Serenace</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Haldol | Haldol decanoas</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Haldol</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Haldol</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Decan haloper | Furp haloperidol | Haldol | Haldol decanoato | Halo | Halo decanoato | Haloper | Loperidol | Uni haloper</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Haldol | Haldol decanoas | Sigaperidol</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Haldol | Haldol decanoato | Nurox</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Haldol</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Apracal | Halopidol | Halopidol decanoato</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo haloperidol | Haloperidol decanoat</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Buteridol | Haldol | Haldol decanoat | Haloneural | Haloper CT | Haloperidol desitin | Haloperidol hexal | Sigaperidol</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Serenase</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Butinon | Feltram | Haldol</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Apracal | Dep | Haldol | Haldol decanoas</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Decaldol | Haloperidol decanoate richter | Haloperidol desitin | Haloperidol richter</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Haldol | Halonace | Haloprol | Peridol | Safinace</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Haloperidol esteve | Haloperidol prodes</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Haloperin | Serenase</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Haldol | Haldol decanoas</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Fortunan | Haldol | Haloperidol | Haloperidol cox | Haloperidol dc | Haloperidol kent | Haloperidol sandoz | Haloperidol srl | Serenace</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Alased | Aloperidin | Aloperidin decanoas | Haldol | Haloperidol/ifet | Sevium</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo haloperidol | Haldol | Haldol decanoas | Haloper | Haloperidol neuraxpharm | Haloperidol neuraxpharm decanoate | Halpidol | Serenace | Sereno | Tamide</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Haldol | Haloperidol Krka</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Haloperidol</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Dores | Govotil | Haldol | Lodomer | Seradol | Serenace</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Haldol | Haldol decanoate | Novo-peridol | Serenace</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Haldol | Haldol decanoate | Haloper | Pericate | Peridor</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Agidol | Andol 10 | Andol 5 | Benzydol-p | Brain rest | Cizoren | Depidol | Dolteus | Haldol | Halidace | Halobid | Halodep t | Halodol | Halopace | Halopidol | Haloshine | Helinase | Hexidol | Larenase | Manonace | Mindol | Mindwel | Normadol | Qutzal | Randro | Relinase | Relinase-la | Schizol | Senorm | Seradol | Serenace | Talendol | Trancodol | Trikonace | Typidol</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Haldol | Haldol decanoas | Serenase</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Haldol | Haloxen | Serenace</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Brotopon | Cosminal | Einalon s | Esextin mita | Halomidol | Halomidol amel | Halomidol choseido | Halomidol merck hoei | Halomonth | Haloperidol Amel | Haloperidol merck | Haloperidol Mylan | Haloperidol taisho | Haloperidol Tsuruhara | Halosten | Helparol | Keselan | Lemonamin | Linton | Mixidol | Neoperidol | Parosmin | Peluces | Phlogis | Serenace | Suirolin | Trakimin</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Halomed | Heridol | Senorm | Serenace</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">H.p | Haldol decanoas | Halopen | Myungin haloperidol | Peridol | Serenace</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Haldol</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Haldol | Haldol decanoas | Halperol</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Apo haloperidol | Avant | Haldol | Haloper | Heloper l.a. | Senorm</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Haldol | Haldol decanoas</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Apo haloperidol | Haldol | Haloperidol richter | Senorm</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Apo-peridol | Haldol</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Gaventis | Haldol | Haldol decanoas | Haloperidol | Haloperil | Peridol | Pulsit | Pulsit lp</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo haloperidol | Hadol-5 | Mapress | Motivan | Serenace</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Calmperidol | Halolem | Surelife haloperidol</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Haldol | Haloperidol CF</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Haldol | Haloperidol neuraxpharm | Haloperidol ratiopharm</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Haldol | Haloperidol | Serenace</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Akroperidol decanoato | Haldol | Haldol decanoas | Halperil</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Haldol | Haldol decanoas | Loridol | Seredol Deca | Serenace | Zuredel</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Ceretek | Dosik | Gt dol | Haldol | Halodol | Halotec depot | Halotec plain | Hepdol | Phrenia | Sera | Seredol | Serenace</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Decaldol</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Haldol | Haldol decanoate | Haloperidol | Haloperidol decanoate vh</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Haldol | Haldol decanoato | Serenelfi</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Akroperidol | Akroperidol decanoato | Anactivan | Haloperidol decanoato | Loperil | Psicodol | Sutranx</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Haldol | Haldol Decanoate | Haldol Lactate | Haloxen</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Haldol | Haloper | Haloperidol arena | Haloperidol decanoat | Haloperidol eel | Haloperidol laropharm | Haloperidol richter</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Apo haloperidol | Haloper | Haloperidol | Haloperidol akri | Haloperidol decan | Haloperidol ferein | Haloperidol richter | Senorm</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo haloperidol | Haldol | Serenace</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Haldol</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo haloperidol | Mapress | Motivan | Serenace</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Haldol</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Haloperidol decanoat</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Arom | Avant | Haldol | Halidol | Halo p | Haloden | Halolop | Halomed | Halopin | Halopol | Halotab | Halox | Haperdol | Haricon | Haridol | Perida | Polyhadol | Schizopol | Serenace | T Dol | Tenlo | Tensidol</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Haldol | Haldol decanoas | Halidol</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Haldol | Norodol | Norodol Dekanoat</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Ansolin | Apo haloperidol | Avant | Binin-u | Gynedol | Haldecan | Haldol | Haldolin | Halin | Halolium | Haloperidol decanoat | Haloperidol Toho | Haloperin | Halopin | Halosten | Haloxen | Hopan | Inin | Serenace | U-dolan</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Apo haloperidol | Galopril | Galopril forte | Haloper | Haloperidol forte | Halopril | Senorm</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Agohal | Haloxen</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Akroperidol | Akroperidol decanoato | Fuperidol | Haldol | Haloretard</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Haldol | Haridol</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Gulf haloperidol | Haloperidol oethmaan | Rolab-haloperidol | Serenace</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Peridol</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28764561">
<a name="28764561"></a>Abidi S, Mian I, Garcia-Ortega I, et al. Canadian guidelines for the pharmacological treatment of schizophrenia spectrum and other psychotic disorders in children and youth. <i>Can J Psychiatry</i>. 2017;62(9):635-647. doi:10.1177/0706743717720197<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/28764561/pubmed" id="28764561" target="_blank">28764561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18378767">
<a name="18378767"></a>ACOG Committee on Practice Bulletins-Obstetrics, "ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 92, April 2008 (Replaces Practice Bulletin Number 87, November 2007). Use of Psychiatric Medications During Pregnancy and Lactation," <i>Obstet Gynecol</i>, 2008, 111(4):1001-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/18378767/pubmed" id="18378767" target="_blank">18378767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14662555">
<a name="14662555"></a>Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. <i>Arch Gen Psychiatry.</i> 2003;60(12):1228-1235. doi:10.1001/archpsyc.60.12.1228<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/14662555/pubmed" id="14662555" target="_blank">14662555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31524318">
<a name="31524318"></a>Alonso-Pedrero L, Bes-Rastrollo M, Marti A. Effects of antidepressant and antipsychotic use on weight gain: a systematic review. <i>Obes Rev</i>. 2019;20(12):1680-1690. doi:10.1111/obr.12934<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/31524318/pubmed" id="31524318" target="_blank">31524318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20210726">
<a name="20210726"></a>Alvarez PA, Pahissa J. QT alterations in psychopharmacology: proven candidates and suspects. <i>Curr Drug Saf</i>. 2010;5(1):97-104. doi:10.2174/157488610789869265<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/20210726/pubmed" id="20210726" target="_blank">20210726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15003083">
<a name="15003083"></a>American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. <i>J Clin Psychiatry</i>. 2004;65(2):267-272.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/15003083/pubmed" id="15003083" target="_blank">15003083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36286254">
<a name="36286254"></a>Andersen-Ranberg NC, Poulsen LM, Perner A, et al; AID-ICU Trial Group. Haloperidol for the treatment of delirium in ICU patients. <i>N Engl J Med</i>. 2022;387(26):2425-2435. doi:10.1056/NEJMoa2211868<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/36286254/pubmed" id="36286254" target="_blank">36286254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28861176">
<a name="28861176"></a>Annamalai A, Kosir U, Tek C. Prevalence of obesity and diabetes in patients with schizophrenia. <i>World J Diabetes</i>. 2017;8(8):390-396. doi:10.4239/wjd.v8.i8.390<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/28861176/pubmed" id="28861176" target="_blank">28861176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30375086">
<a name="30375086"></a>Anzai T, Takahashi K, Watanabe M. Adverse reaction reports of neuroleptic malignant syndrome induced by atypical antipsychotic agents in the Japanese Adverse Drug Event Report (JADER) database. <i>Psychiatry Clin Neurosci</i>. 2019;73(1):27-33. doi:10.1111/pcn.12793<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/30375086/pubmed" id="30375086" target="_blank">30375086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20361897">
<a name="20361897"></a>Arakawa R, Okumura M, Ito H, et al. Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia. <i>J Clin Psychiatry</i>. 2010;71(9):1131-1137. doi:10.4088/JCP.08m04307yel<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/20361897/pubmed" id="20361897" target="_blank">20361897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3979264">
<a name="3979264"></a>Bach DS, Rybak MJ. Haloperidol-associated hyperthermia. <i>Drug Intell Clin Pharm</i>. 1985;19(3):211. doi:10.1177/106002808501900313<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/3979264/pubmed" id="3979264" target="_blank">3979264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28979025">
<a name="28979025"></a>Balai M, Ansari F, Gupta LK, Khare AK, Mittal AK. Urticaria and angioedema associated with haloperidol. <i>Indian J Dermatol</i>. 2017;62(5):539-540. doi:10.4103/ijd.IJD_257_17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/28979025/pubmed" id="28979025" target="_blank">28979025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19138567">
<a name="19138567"></a>Ballard C, Hanney ML, Theodoulou M, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. <i>Lancet Neurol</i>. 2009;8(2):151-157. doi:10.1016/S1474-4422(08)70295-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/19138567/pubmed" id="19138567" target="_blank">19138567</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3567823">
<a name="3567823"></a>Balon R, Berchou R, Zethelius M. Thrombocytopenia associated with chlorpromazine, haloperidol and thiothixene: a case report. <i>Can J Psychiatry</i>. 1987;32(2):149-150. doi:10.1177/070674378703200213<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/3567823/pubmed" id="3567823" target="_blank">3567823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9712220">
<a name="9712220"></a>Bark N. Deaths of psychiatric patients during heat waves. <i>Psychiatr Serv</i>. 1998;49(8):1088-1090. doi:10.1176/ps.49.8.1088<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/9712220/pubmed" id="9712220" target="_blank">9712220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22250654">
<a name="22250654"></a>Baweja R, Sedky K, Lippmann S. Long-acting antipsychotic medications. <i>Curr Drug Targets</i>. 2012;13(4):555-560.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/22250654/pubmed" id="22250654" target="_blank">22250654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23295003">
<a name="23295003"></a>Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC. QTc prolongation, torsades de pointes, and psychotropic medications. <i>Psychosomatics</i>. 2013;54(1):1-13. doi:10.1016/j.psym.2012.11.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/23295003/pubmed" id="23295003" target="_blank">23295003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29275963">
<a name="29275963"></a>Beach SR, Celano CM, Sugrue AM, et al. QT Prolongation, torsades de pointes, and psychotropic medications: a 5-year update. <i>Psychosomatics</i>. 2018;59(2):105-122. doi:10.1016/j.psym.2017.10.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/29275963/pubmed" id="29275963" target="_blank">29275963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19276778">
<a name="19276778"></a>Bellamy CJ, Kane-Gill SL, Falcione BA, Seybert AL. Neuroleptic malignant syndrome in traumatic brain injury patients treated with haloperidol. <i>J Trauma</i>. 2009;66(3):954-958. doi:10.1097/TA.0b013e31818e90ed<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/19276778/pubmed" id="19276778" target="_blank">19276778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25578944">
<a name="25578944"></a>Belvederi Murri M, Guaglianone A, Bugliani M, et al. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. <i>Drugs R D</i>. 2015;15(1):45-62. doi:10.1007/s40268-014-0078-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/25578944/pubmed" id="25578944" target="_blank">25578944</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23983836">
<a name="23983836"></a>Berman BD. Neuroleptic malignant syndrome: a review for neurohospitalists. <i>Neurohospitalist</i>. 2011;1(1):41-47. doi:10.1177/1941875210386491<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/23983836/pubmed" id="23983836" target="_blank">23983836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19958039">
<a name="19958039"></a>Bhuvaneswar CG, Baldessarini RJ, Harsh VL, Alpert JE. Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review. <i>CNS Drugs</i>. 2009;23(12):1003-1021. doi:10.2165/11530020-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/19958039/pubmed" id="19958039" target="_blank">19958039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26242478">
<a name="26242478"></a>Bloechliger M, Rüegg S, Jick SS, Meier CR, Bodmer M. Antipsychotic drug use and the risk of seizures: follow-up study with a nested case-control analysis. <i>CNS Drugs</i>. 2015;29(7):591-603. doi:10.1007/s40263-015-0262-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/26242478/pubmed" id="26242478" target="_blank">26242478</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12623765">
<a name="12623765"></a>Bobes J, Garc A-Portilla MP, Rejas J, et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. <i>J Sex Marital Ther</i>. 2003;29(2):125-147. doi:10.1080/713847170<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/12623765/pubmed" id="12623765" target="_blank">12623765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19113797">
<a name="19113797"></a>Bostwick JR, Guthrie SK, Ellingrod VL. Antipsychotic-induced hyperprolactinemia. <i>Pharmacotherapy</i>. 2009;29(1):64-73. doi:10.1592/phco.29.1.64<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/19113797/pubmed" id="19113797" target="_blank">19113797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17698676">
<a name="17698676"></a>Bouchama A, Dehbi M, Mohamed G, Matthies F, Shoukri M, Menne B. Prognostic factors in heat wave related deaths: a meta-analysis. <i>Arch Intern Med</i>. 2007;167(20):2170-2176. doi:10.1001/archinte.167.20.ira70009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/17698676/pubmed" id="17698676" target="_blank">17698676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8808357">
<a name="8808357"></a>Brown RL, Henke A, Greenhalgh DG, Warden GD. The use of haloperidol in the agitated, critically ill pediatric patient with burns. <i>J Burn Care Rehabil</i>. 1996;17(1):34-38.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/8808357/pubmed" id="8808357" target="_blank">8808357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32345400">
<a name="32345400"></a>Burbuqe I, Boettger S, Schubert M, Bettex D, Rudiger A. QTc prolongation after haloperidol administration in critically ill patients post cardiovascular surgery: a cohort study and review of the literature. <i>Palliat Support Care</i>. 2020;18(4):447-459. doi:10.1017/S1478951520000231<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/32345400/pubmed" id="32345400" target="_blank">32345400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15564955">
<a name="15564955"></a>Büttner M, Walder B, von Elm E, Tramèr MR. Is low-dose haloperidol a useful antiemetic?: A meta-analysis of published and unpublished randomized trials. <i>Anesthesiology</i>. 2004;101(6):1454-1463.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/15564955/pubmed" id="15564955" target="_blank">15564955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16529334">
<a name="16529334"></a>Canadian Psychiatric Association (CPA). Clinical practice guidelines. Treatment of schizophrenia. <i>Can J Psychiatry</i>. 2005;50(13)(suppl 1):7S-57S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/16529334/pubmed" id="16529334" target="_blank">16529334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28146614">
<a name="28146614"></a>Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. <i>J Clin Psychiatry</i>. 2017;78(3):e264-e278. doi:10.4088/JCP.16r10832<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/28146614/pubmed" id="28146614" target="_blank">28146614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12927004">
<a name="12927004"></a>Carlson CD, Cavazzoni PA, Berg PH, Wei H, Beasley CM, Kane JM. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. <i>J Clin Psychiatry</i>. 2003;64(8):898-906. doi:10.4088/jcp.v64n0807<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/12927004/pubmed" id="12927004" target="_blank">12927004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21172575">
<a name="21172575"></a>Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. <i>Neurol Clin</i>. 2011;29(1):127-viii. doi:10.1016/j.ncl.2010.10.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/21172575/pubmed" id="21172575" target="_blank">21172575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32614955">
<a name="32614955"></a>Castro E, Körver F, Merry A, et al. Should we still monitor QTc duration in frail older patients on low-dose haloperidol? A prospective observational cohort study. <i>Age Ageing</i>. 2020;49(5):829-836. doi:10.1093/ageing/afaa066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/32614955/pubmed" id="32614955" target="_blank">32614955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23821039">
<a name="23821039"></a>Cerovecki A, Musil R, Klimke A, et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. <i>CNS Drugs</i>. 2013;27(7):545-572. doi: 10.1007/s40263-013-0079-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/23821039/pubmed" id="23821039" target="_blank">23821039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chen.2012">
<a name="Chen.2012"></a>Chen JJ. Drug-induced movement disorders. <i>Mental Health Clinician</i>. 2012;1(7):167-173. doi: 10.9740/mhc.n90206</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15888517">
<a name="15888517"></a>Christodoulou C, Kalaitzi C. Antipsychotic drug-induced acute laryngeal dystonia: two case reports and a mini review. <i>J Psychopharmacol</i>. 2005;19(3):307-311. doi:10.1177/0269881105051543<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/15888517/pubmed" id="15888517" target="_blank">15888517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16856043">
<a name="16856043"></a>Cipriani A, Rendell JM, Geddes JR. Haloperidol alone or in combination for acute mania. <i>Cochrane Database Syst Rev</i>. 2006;(3)CD004362.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/16856043/pubmed" id="16856043" target="_blank">16856043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3813167">
<a name="3813167"></a>Clinton JE, Sterner S, Stelmachers Z, Ruiz E. Haloperidol for sedation of disruptive emergency patients. <i>Ann Emerg Med</i>. 1987;16(3):319-322.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/3813167/pubmed" id="3813167" target="_blank">3813167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14992963">
<a name="14992963"></a>Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. <i>Am J Psychiatry</i>. 2004;161(3):414-425. doi:10.1176/appi.ajp.161.3.414<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/14992963/pubmed" id="14992963" target="_blank">14992963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22281201">
<a name="22281201"></a>Corripio I, Ferreira A, Portella MJ, et al. The role of striatal dopamine D2 receptors in the occurrence of extrapyramidal side effects: iodine-123-iodobenzamide single photon emission computed tomography study. <i>Psychiatry Res</i>. 2012;201(1):73-77. doi:10.1016/j.pscychresns.2011.02.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/22281201/pubmed" id="22281201" target="_blank">22281201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30942323">
<a name="30942323"></a>Couto J, Dos Santos LP, Mendes T, López R. Life-threatening hypoglycemia attributable to haloperidol in a patient with schizophrenia. <i>Braz J Psychiatry</i>. 2019;41(2):190-191. doi:10.1590/1516-4446-2018-0356<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/30942323/pubmed" id="30942323" target="_blank">30942323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26237252">
<a name="26237252"></a>Cox JH, Seri S, Cavanna AE. Clinical guidelines on long-term pharmacotherapy for bipolar disorder in children and adolescents. <i>J Clin Med</i>. 2014;3(1):135-143. doi:10.3390/jcm3010135<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/26237252/pubmed" id="26237252" target="_blank">26237252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9376336">
<a name="9376336"></a>Crawford AM, Beasley CM Jr, Tollefson GD. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. <i>Schizophr Res</i>. 1997;26(1):41-54. doi:10.1016/S0920-9964(97)00036-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/9376336/pubmed" id="9376336" target="_blank">9376336</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29955499">
<a name="29955499"></a>Crouse EL, Alastanos JN, Bozymski KM, Toscano RA. Dysphagia with second-generation antipsychotics: a case report and review of the literature. <i>Ment Health Clin</i>. 2018;7(2):56-64. doi:10.9740/mhc.2017.03.056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/29955499/pubmed" id="29955499" target="_blank">29955499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6844982">
<a name="6844982"></a>Cruz FG, Thiagarajan D, Harney JH. Neuroleptic malignant syndrome after haloperidol therapy. <i>South Med J</i>. 1983;76(5):684-686. doi:10.1097/00007611-198305000-00044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/6844982/pubmed" id="6844982" target="_blank">6844982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-513257">
<a name="513257"></a>Cutler NR, Heiser JF. Leukopenia following treatment with thiothixene and haloperidol. <i>JAMA</i>. 1979;242(26):2872-2873.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/513257/pubmed" id="513257" target="_blank">513257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28049388">
<a name="28049388"></a>D’Angelo RG, Rincavage M, Tata AL, et al. Impact of an antipsychotic discontinuation bundle during transitions of care in critically ill patients. <i>J Intensive Care Med</i>. 2019;34(1):40-47. doi: 10.1177/0885066616686741.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/28049388/pubmed" id="28049388" target="_blank">28049388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8830064">
<a name="8830064"></a>Darby JK, Pasta DJ, Dabiri L, Clark L, Mosbacher D. Haloperidol dose and blood level variability: toxicity and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. <i>J Clin Psychopharmacol</i>. 1995;15(5):334-340.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/8830064/pubmed" id="8830064" target="_blank">8830064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11048906">
<a name="11048906"></a>David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. <i>Clin Ther</i>. 2000;22(9):1085-1096. doi:10.1016/S0149-2918(00)80086-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/11048906/pubmed" id="11048906" target="_blank">11048906</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34398289">
<a name="34398289"></a>Davis M, Hui D, Davies A, et al. MASCC antiemetics in advanced cancer updated guideline. <i>Support Care Cancer</i>. 2021;29(12):8097-8107. doi:10.1007/s00520-021-06437-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/34398289/pubmed" id="34398289" target="_blank">34398289</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28883731">
<a name="28883731"></a>Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. <i>Neuropsychiatr Dis Treat</i>. 2017;13:2231-2241. doi:10.2147/NDT.S113099<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/28883731/pubmed" id="28883731" target="_blank">28883731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22009159">
<a name="22009159"></a>De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. <i>Nat Rev Endocrinol</i>. 2011;8(2):114-126. doi:10.1038/nrendo.2011.156<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/22009159/pubmed" id="22009159" target="_blank">22009159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DelFabbro.1">
<a name="DelFabbro.1"></a>Del Fabbro E. Assessment and management of nausea and vomiting in palliative care. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16401649">
<a name="16401649"></a>Delieu JM, Horobin RW, Duguid JK. Formation of immature neutrophil leucocytes in schizophrenic patients treated with various antipsychotic drugs: comparisons and predictions. <i>J Psychopharmacol</i>. 2006;20(6):824-828. doi:10.1177/0269881106061112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/16401649/pubmed" id="16401649" target="_blank">16401649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30113379">
<a name="30113379"></a>Devlin JW, Skrobik Y, Gélinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. <i>Crit Care Med</i>. 2018;46(9):e825-e873. doi: 10.1097/CCM.0000000000003299.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/30113379/pubmed" id="30113379" target="_blank">30113379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15766297">
<a name="15766297"></a>Diav-Citrin O, Shechtman S, Ornoy S, et al, "Safety of Haloperidol and Penfluridol in Pregnancy: A Multicenter, Prospective, Controlled Study," <i>J Clin Psychiatry</i>, 2005, 66(3):317-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/15766297/pubmed" id="15766297" target="_blank">15766297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26392457">
<a name="26392457"></a>Digby G, Jalini S, Taylor S. Medication-induced acute dystonic reaction: the challenge of diagnosing movement disorders in the intensive care unit. <i>BMJ Case Rep</i>. 2015;2015:bcr2014207215. doi:10.1136/bcr-2014-207215<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/26392457/pubmed" id="26392457" target="_blank">26392457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28360627">
<a name="28360627"></a>Doğan Bulut S, Bulut S, Tüzer V, et al. The effects of prolactin-raising and prolactin-sparing antipsychotics on prolactin levels and bone mineral density in schizophrenic patients. <i>Noro Psikiyatr Ars</i>. 2014;51(3):205-210. doi:10.4274/npa.y6628<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/28360627/pubmed" id="28360627" target="_blank">28360627</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10878638">
<a name="10878638"></a>Douglas PH, Block PC. Corrected QT interval prolongation associated with intravenous haloperidol in acute coronary syndromes. <i>Catheter Cardiovasc Interv</i>. 2000;50(3):352-355. doi:10.1002/1522-726x(200007)50:3&lt;352::aid-ccd19&gt;3.0.co;2-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/10878638/pubmed" id="10878638" target="_blank">10878638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20142454">
<a name="20142454"></a>Drew BJ, Ackerman MJ, Funk M, et al; American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology, the Council on Cardiovascular Nursing, and the American College of Cardiology Foundation. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation [published correction appears in <i>Circulation</i>. 2010;122(8):e440]. <i>Circulation</i>. 2010;121(8):1047-1060. doi: 10.1161/CIRCULATIONAHA.109.192704.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/20142454/pubmed" id="20142454" target="_blank">20142454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29256130">
<a name="29256130"></a>Drobnis EZ, Nangia AK. Antimicrobials and male reproduction. <i>Adv Exp Med Biol</i>. 2017;1034:131-161. doi:10.1007/978-3-319-69535-8_10<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/29256130/pubmed" id="29256130" target="_blank">29256130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19494785">
<a name="19494785"></a>Duncan EJ, Woolson SL, Hamer RM, Dunlop BW. Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population. <i>Int Clin Psychopharmacol</i>. 2009;24(4):204-213. doi:10.1097/YIC.0b013e32832d6c18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/19494785/pubmed" id="19494785" target="_blank">19494785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17024549">
<a name="17024549"></a>Dziewas R, Warnecke T, Schnabel M, et al. Neuroleptic-induced dysphagia: case report and literature review. <i>Dysphagia</i>. 2007;22(1):63-67. doi:10.1007/s00455-006-9032-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/17024549/pubmed" id="17024549" target="_blank">17024549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31306860">
<a name="31306860"></a>Elbakary NAH, Ouanes S. First generation antipsychotic-induced severe hypothermia: a case report and review of the literature. <i>Asian J Psychiatr</i>. 2019;44:35-37. doi:10.1016/j.ajp.2019.07.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/31306860/pubmed" id="31306860" target="_blank">31306860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2371365">
<a name="2371365"></a>Ereshefsky L, Saklad SR, Tran-Johnson T, Toney G, Lyman RC, Davis CM. Kinetics and clinical evaluation of haloperidol decanoate loading dose regimen. <i>Psychopharmacol Bull</i>. 1990;26(1):108-114.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/2371365/pubmed" id="2371365" target="_blank">2371365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7907570">
<a name="7907570"></a>Ereshefsky L, Toney G, Saklad SR, Anderson C, Seidel D. A loading-dose strategy for converting from oral to depot haloperidol. <i>Hosp Community Psychiatry</i>. 1993;44(12):1155-1161.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/7907570/pubmed" id="7907570" target="_blank">7907570</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17414689">
<a name="17414689"></a>Evcimen H, Alici-Evcimen Y, Basil B, Mania I, Mathews M, Gorman JM. Neuroleptic malignant syndrome induced by low dose aripiprazole in first episode psychosis. <i>J Psychiatr Pract</i>. 2007;13(2):117-119. doi:10.1097/01.pra.0000265770.17871.01<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/17414689/pubmed" id="17414689" target="_blank">17414689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Feinleib.1">
<a name="Feinleib.1"></a>Feinleib J, Kwan LH, Yamani A. Postoperative nausea and vomiting. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 5, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18098216">
<a name="18098216"></a>Flanagan RJ, Dunk L. Haematological toxicity of drugs used in psychiatry. <i>Hum Psychopharmacol</i>. 2008;23 Suppl 1:27-41. doi:10.1002/hup.917<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/18098216/pubmed" id="18098216" target="_blank">18098216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-822989">
<a name="822989"></a>Forsman A, Ohman R. Pharmacokinetic studies on haloperidol in man. <i>Curr Ther Res Clin Exp</i>. 1976;20(3):319-336.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/822989/pubmed" id="822989" target="_blank">822989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Francis.1">
<a name="Francis.1"></a>Francis JF. Delirium and acute confusional states: Prevention, treatment, and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 30, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fuhrman.1">
<a name="Fuhrman.1"></a>Fuhrman B, Zimmerman J, eds.<i> Pediatric Critical Care</i>. 5th ed. Elsevier Health; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32467512">
<a name="32467512"></a>Gan TJ, Belani KG, Bergese S, et al. Fourth consensus guidelines for the management of postoperative nausea and vomiting. <i>Anesth Analg</i>. 2020;131(2):411-448. doi:10.1213/ANE.0000000000004833<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/32467512/pubmed" id="32467512" target="_blank">32467512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18344731">
<a name="18344731"></a>Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. <i>J Clin Psychopharmacol</i>. 2008;28(2):203-209. doi:10.1097/JCP.0b013e318166c4d5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/18344731/pubmed" id="18344731" target="_blank">18344731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30881565">
<a name="30881565"></a>Gerson R, Malas N, Feuer V, Silver GH, Prasad R, Mroczkowski MM. Best practices for evaluation and treatment of agitated children and adolescents (BETA) in the emergency department: consensus statement of the American Association for Emergency Psychiatry. <i>West J Emerg Med</i>. 2019;20(2):409-418. doi:10.5811/westjem.2019.1.41344<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/30881565/pubmed" id="30881565" target="_blank">30881565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10798826">
<a name="10798826"></a>Ghani SO, Ahmed W, Marco LA. Neuroleptic malignant syndrome and severe thrombocytopenia: case report and literature review. <i>Ann Clin Psychiatry</i>. 2000;12(1):51-54. doi:10.1023/a:1009079127829<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/10798826/pubmed" id="10798826" target="_blank">10798826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17548409">
<a name="17548409"></a>Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. <i>Ann Intern Med</i>. 2007;146(11):775-786. doi:10.7326/0003-4819-146-11-200706050-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/17548409/pubmed" id="17548409" target="_blank">17548409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23905227">
<a name="23905227"></a>Gillespie M, Toner A. The safe administration of long-acting depot antipsychotics. <i>Br J Nurs</i>. 2013;22(8):464, 466-469.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/23905227/pubmed" id="23905227" target="_blank">23905227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30346242">
<a name="30346242"></a>Girard TD, Exline MC, Carson SS, et al; MIND-USA Investigators. Haloperidol and ziprasidone for treatment of delirium in critical illness. <i>N Engl J Med</i>. 2018;379(26):2506-2516. doi: 10.1056/NEJMoa1808217.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/30346242/pubmed" id="30346242" target="_blank">30346242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19093700">
<a name="19093700"></a>Glare PA, Dunwoodie D, Clark K, et al. Treatment of nausea and vomiting in terminally ill cancer patients. <i>Drugs.</i> 2008;68(18):2575-2590.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/19093700/pubmed" id="19093700" target="_blank">19093700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22841129">
<a name="22841129"></a>Goikolea JM, Colom F, Capapey J, et al. Faster onset of antimanic action with haloperidol compared to second-generation antipsychotics. A meta-analysis of randomized clinical trials in acute mania.<i> Eur Neuropsychopharmacol</i>. 2013;23(4):305-316. doi: 10.1016/j.euroneuro.2012.05.017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/22841129/pubmed" id="22841129" target="_blank">22841129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19047493">
<a name="19047493"></a>Gonzalez F. Extrapyramidal syndrome presenting as dysphagia: a case report. <i>Am J Hosp Palliat Care</i>. 2008;25(5):398-400. doi:10.1177/1049909108322367<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/19047493/pubmed" id="19047493" target="_blank">19047493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26979387">
<a name="26979387"></a>Goodwin GM, Haddad PM, Ferrier IN, et al. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. <i>J Psychopharmacol</i>. 2016;30(6):495-553. doi: 10.1177/0269881116636545.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/26979387/pubmed" id="26979387" target="_blank">26979387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12721815">
<a name="12721815"></a>Gothelf D, Apter A, Reidman J, et al. Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. <i>J Neural Transm (Vienna)</i>. 2003;110(5):545-560. doi:10.1007/s00702-002-0803-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/12721815/pubmed" id="12721815" target="_blank">12721815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19347775">
<a name="19347775"></a>Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania [published correction appears in <i>World J Biol Psychiatry</i>. 2009;10(3):255]. <i>World J Biol Psychiatry.</i> 2009;10(2):85-116. doi: 10.1080/15622970902823202.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/19347775/pubmed" id="19347775" target="_blank">19347775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15456328">
<a name="15456328"></a>Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. <i>Drugs</i>. 2004;64(20):2291-2314. doi:10.2165/00003495-200464200-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/15456328/pubmed" id="15456328" target="_blank">15456328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11199936">
<a name="11199936"></a>Hägg S, Mjörndal T, Lindqvist L. Repeated episodes of hypothermia in a subject treated with haloperidol, levomepromazine, olanzapine, and thioridazine. <i>J Clin Psychopharmacol</i>. 2001;21(1):113-115. doi:10.1097/00004714-200102000-00023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/11199936/pubmed" id="11199936" target="_blank">11199936</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Haldol decanoate injection (haloperidol) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; February 2020.</div>
</li>
<li>
<div class="reference">
                  Haldol decanoate injection (haloperidol) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; November 2020.</div>
</li>
<li>
<div class="reference">
                  Haldol decanoate injection (haloperidol) [product monograph]. Varennes, Quebec, Canada: Strides Pharma Canada Inc; May 2020.</div>
</li>
<li>
<div class="reference">
                  Haldol lactate injection (haloperidol) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; November 2020.</div>
</li>
<li>
<div class="reference">
                  Haloperidol [prescribing information]. Princeton, NJ: Sandoz Inc; September 2008.</div>
</li>
<li>
<div class="reference">
                  Haloperidol [product monograph]. Montreal, Quebec, Canada: Omega Laboratories Limited; December 2023.</div>
</li>
<li>
<div class="reference">
                  Haloperidol Lactate [prescribing information]. Greenville, SC: Pharmaceutical Associates Inc; December 2008.</div>
</li>
<li>
<div class="reference">
                  Haloperidol lactate injection [prescribing information]. Schaumburg, IL: Sagent Pharmaceuticals; August 2011.</div>
</li>
<li>
<div class="reference">
                  Haloperidol lactate oral solution [prescribing information]. Greenville, SC: Pharmaceutical Associates, Inc; November 2016.</div>
</li>
<li>
<div class="reference">
                  Haloperidol lactate oral solution USP (concentrate) [prescribing information]. Greenville, SC: Pharmaceutical Associates, Inc; March 2020.</div>
</li>
<li>
<div class="reference">
                  Haloperidol tablets [prescribing information]. Princeton, NJ: Sandoz Inc; July 2015.</div>
</li>
<li>
<div class="reference">
                  Haloperidol tablets [prescribing information]. Maple Grove, MN: Upsher-Smith Laboratories, LLC; June 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18941580">
<a name="18941580"></a>Hansen A, Bi P, Nitschke M, Ryan P, Pisaniello D, Tucker G. The effect of heat waves on mental health in a temperate Australian city. <i>Environ Health Perspect</i>. 2008;116(10):1369-1375. doi:10.1289/ehp.11339<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/18941580/pubmed" id="18941580" target="_blank">18941580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7891424">
<a name="7891424"></a>Harada H, Igarashi M, Sugae S, Okamoto K, Tsuji M, Nakajima T. A schizophrenic patient who developed extreme hypothermia after an increase in the dose of haloperidol: a case report. <i>Jpn J Psychiatry Neurol</i>. 1994;48(3):595-598. doi:10.1111/j.1440-1819.1994.tb03020.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/7891424/pubmed" id="7891424" target="_blank">7891424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20619214">
<a name="20619214"></a>Hardy JR, O’Shea A, White C, Gilshenan K, Welch L, Douglas C. The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer. <i>J Pain Symptom Manage</i>. 2010;40(1):111-116.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/20619214/pubmed" id="20619214" target="_blank">20619214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Harman.1">
<a name="Harman.1"></a>Harman SM, Walling AM. Palliative care: the last hours and days of life. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 21, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14709949">
<a name="14709949"></a>Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. <i>J Clin Psychopharmacol</i>. 2004;24(1):62-69. doi:10.1097/01.jcp.0000104913.75206.62<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/14709949/pubmed" id="14709949" target="_blank">14709949</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11866368">
<a name="11866368"></a>Harrison AM, Lugo RA, Lee WE, et al. The use of haloperidol in agitated critically ill children.<i> Clin Pediatr (Phila)</i>. 2002;41(1):51-54.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/11866368/pubmed" id="11866368" target="_blank">11866368</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15342619">
<a name="15342619"></a>Harvey AT, Flockhart D, Gorski JC, et al. Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia. <i>J Clin Pharmacol</i>. 2004;44(10):1173-1184. doi:10.1177/0091270004267807<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/15342619/pubmed" id="15342619" target="_blank">15342619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23216388">
<a name="23216388"></a>Hasan A, Falkai P, Wobrock T, et al; WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. <i>World J Biol Psychiatry</i>. 2013;14(1):2-44. doi: 10.3109/15622975.2012.739708.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/23216388/pubmed" id="23216388" target="_blank">23216388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22834451">
<a name="22834451"></a>Hasan A, Falkai P, Wobrock T, et al; World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. <i>World J Biol Psychiatry</i>. 2012;13(5):318-378. doi: 10.3109/15622975.2012.696143.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/22834451/pubmed" id="22834451" target="_blank">22834451</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25822804">
<a name="25822804"></a>Hasan A, Falkai P, Wobrock T, et al; WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia. part 3: update 2015 management of special circumstances: depression, suicidality, substance use disorders and pregnancy and lactation. <i>World J Biol Psychiatry</i>. 2015;16(3):142-170. doi:10.3109/15622975.2015.1009163<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/25822804/pubmed" id="25822804" target="_blank">25822804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14585064">
<a name="14585064"></a>Hassaballa HA, Balk RA. Torsade de pointes associated with the administration of intravenous haloperidol: a review of the literature and practical guidelines for use. <i>Expert Opin Drug Saf</i>. 2003;2(6):543-547.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/14585064/pubmed" id="14585064" target="_blank">14585064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12973403">
<a name="12973403"></a>Hedges D, Jeppson K, Whitehead P. Antipsychotic medication and seizures: a review. <i>Drugs Today (Barc)</i>. 2003;39(7):551-557. doi:10.1358/dot.2003.39.7.799445<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/12973403/pubmed" id="12973403" target="_blank">12973403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29095482">
<a name="29095482"></a>Herzig SJ, LaSalvia MT, Naidus E, et al. Antipsychotics and the risk of aspiration pneumonia in individuals hospitalized for nonpsychiatric conditions: a cohort study. <i>J Am Geriatr Soc</i>. 2017;65(12):2580-2586. doi: 10.1111/jgs.15066.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/29095482/pubmed" id="29095482" target="_blank">29095482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hesketh.1">
<a name="Hesketh.1"></a>Hesketh PJ. Management of poorly controlled or breakthrough chemotherapy-induced nausea and vomiting in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32658626">
<a name="32658626"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. <i>J Clin Oncol</i>. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/32658626/pubmed" id="32658626" target="_blank">32658626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28910830">
<a name="28910830"></a>Hiemke C, Bergemann N, Clement HW,et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. <i>Pharmacopsychiatry</i>. 2018;51(1-02):9-62. doi:10.1055/s-0043-116492<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/28910830/pubmed" id="28910830" target="_blank">28910830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6831826">
<a name="6831826"></a>Holley FO, Magliozzi JR, Stanski DR, Lombrozo L, Hollister LE. Haloperidol kinetics after oral and intravenous doses. <i>Clin Pharmacol Ther</i>. 1983;33(4):477-484.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/6831826/pubmed" id="6831826" target="_blank">6831826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9359953">
<a name="9359953"></a>Holloman LC, Marder SR. Management of acute extrapyramidal effects induced by antipsychotic drugs. <i>Am J Health Syst Pharm</i>. 1997;54(21):2461-2477. doi:10.1093/ajhp/54.21.2461<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/9359953/pubmed" id="9359953" target="_blank">9359953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10671383">
<a name="10671383"></a>Howard R, Rabins PV, Seeman MV, Jeste DV. Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. The International Late-Onset Schizophrenia Group. <i>Am J Psychiatry</i>. 2000;157(2):172-178. doi:10.1176/appi.ajp.157.2.172<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/10671383/pubmed" id="10671383" target="_blank">10671383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24967672">
<a name="24967672"></a>Howland RH. The comparative cardiac effects of haloperidol and quetiapine: parsing a review. <i>J Psychosoc Nurs Ment Health Serv</i>. 2014;52(6):23-26. doi:10.3928/02793695-20140515-01<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/24967672/pubmed" id="24967672" target="_blank">24967672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29924506">
<a name="29924506"></a>Hsu JH, Mulsant BH, Lenze EJ, et al. Clinical predictors of extrapyramidal symptoms associated with aripiprazole augmentation for the treatment of late-life depression in a randomized controlled trial. <i>J Clin Psychiatry</i>. 2018;79(4):17m11764. doi:10.4088/JCP.17m11764<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/29924506/pubmed" id="29924506" target="_blank">29924506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26323511">
<a name="26323511"></a>Isenberg DL, Jacobs D. Prehospital agitation and sedation trial (PhAST): a randomized control trial of intramuscular haloperidol versus intramuscular midazolam for the sedation of the agitated or violent patient in the prehospital environment. <i>Prehosp Disaster Med</i>. 2015;30(5):491-495. doi:10.1017/S1049023X15004999<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/26323511/pubmed" id="26323511" target="_blank">26323511</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25140533">
<a name="25140533"></a>Jackson JW, Schneeweiss S, VanderWeele TJ, Blacker D. Quantifying the role of adverse events in the mortality difference between first and second-generation antipsychotics in older adults: systematic review and meta-synthesis. <i>PLoS One</i>. 2014;9(8):e105376. doi:10.1371/journal.pone.0105376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/25140533/pubmed" id="25140533" target="_blank">25140533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11902253">
<a name="11902253"></a>Jacobi J, Fraser GL, Coursin DB; Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM), American Society of Health-System Pharmacists (ASHP), American College of Chest Physicians. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. <i>Crit Care Med</i>. 2002;30(1):119-141.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/11902253/pubmed" id="11902253" target="_blank">11902253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jibson.1">
<a name="Jibson.1"></a>Jibson MD. First-generation antipsychotic medications: pharmacology, administration, and comparative side effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 30, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16282852">
<a name="16282852"></a>Jung DU, Seo YS, Park JH, et al. The prevalence of hyperprolactinemia after long-term haloperidol use in patients with chronic schizophrenia. <i>J Clin Psychopharmacol</i>. 2005;25(6):613-615. doi:10.1097/01.jcp.0000186738.84276.9f<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/16282852/pubmed" id="16282852" target="_blank">16282852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3819263">
<a name="3819263"></a>Jurivich DA, Hanlon J, Andolsek K. Neuroleptic-induced neutropenia in the elderly. <i>J Am Geriatr Soc</i>. 1987;35(3):248-250. doi:10.1111/j.1532-5415.1987.tb02317.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/3819263/pubmed" id="3819263" target="_blank">3819263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22193526">
<a name="22193526"></a>Kales HC, Kim HM, Zivin K, et al. Risk of mortality among individual antipsychotics in patients with dementia. <i>Am J Psychiatry</i>. 2012;169(1):71-79. doi:10.1176/appi.ajp.2011.11030347<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/22193526/pubmed" id="22193526" target="_blank">22193526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7494570">
<a name="7494570"></a>Kane JM. Schizophrenia. <i>N Engl J Med.</i> 1996;334(1):34-41. doi:10.1056/NEJM199601043340109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/7494570/pubmed" id="7494570" target="_blank">7494570</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32867516">
<a name="32867516"></a>Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. <i>Am J Psychiatry</i>. 2020;177(9):868-872. doi:10.1176/appi.ajp.2020.177901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/32867516/pubmed" id="32867516" target="_blank">32867516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10958256">
<a name="10958256"></a>King DJ, Wager E. Haematological safety of antipsychotic drugs. <i>J Psychopharmacol</i>. 1998;12(3):283-288. doi:10.1177/026988119801200309<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/10958256/pubmed" id="10958256" target="_blank">10958256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29885904">
<a name="29885904"></a>Klein LR, Driver BE, Miner JR, et al. Intramuscular midazolam, olanzapine, ziprasidone, or haloperidol for treating acute agitation in the emergency department. <i>Ann Emerg Med</i>. 2018;72(4):374-385. doi: 10.1016/j.annemergmed.2018.04.027.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/29885904/pubmed" id="29885904" target="_blank">29885904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM, Stanton BF, St. Geme Ill JW, Schor NF, Behrman RE, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Elsevier Saunders; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.2">
<a name="Kliegman.2"></a>Kliegman RM and St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12766935">
<a name="12766935"></a>Kogoj A, Velikonja I. Olanzapine induced neuroleptic malignant syndrome--a case review. <i>Hum Psychopharmacol</i>. 2003;18(4):301-309. doi:10.1002/hup.483<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/12766935/pubmed" id="12766935" target="_blank">12766935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19955388">
<a name="19955388"></a>Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB; Schizophrenia Patient Outcomes Research Team (PORT). The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. <i>Schizophr Bull</i>. 2010;36(1):94-103. doi:10.1093/schbul/sbp130<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/19955388/pubmed" id="19955388" target="_blank">19955388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10628896">
<a name="10628896"></a>Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update. <i>Clin Pharmacokinet</i>. 1999;73(6):435-456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/10628896/pubmed" id="10628896" target="_blank">10628896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35287638">
<a name="35287638"></a>Kuo CW, Yang SC, Shih YF, Liao XM, Lin SH. Typical antipsychotics is associated with increased risk of severe exacerbation in asthma patients: a nationwide population-based cohort study. <i>BMC Pulm Med</i>. 2022;22(1):85. doi:10.1186/s12890-022-01883-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/35287638/pubmed" id="35287638" target="_blank">35287638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16174785">
<a name="16174785"></a>Kwok JS, Chan TY. Recurrent heat-related illnesses during antipsychotic treatment. <i>Ann Pharmacother</i>. 2005;39(11):1940-1942.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/16174785/pubmed" id="16174785" target="_blank">16174785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23737244">
<a name="23737244"></a>La Torre A, Conca A, Duffy D, Giupponi G, Pompili M, Grözinger M. Sexual dysfunction related to psychotropic drugs: a critical review part II: antipsychotics. <i>Pharmacopsychiatry</i>. 2013;46(6):201-208. doi:10.1055/s-0033-1347177<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/23737244/pubmed" id="23737244" target="_blank">23737244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17650054">
<a name="17650054"></a>Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. <i>J Clin Psychiatry</i>. 2007;68(suppl 6):10-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/17650054/pubmed" id="17650054" target="_blank">17650054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24016844">
<a name="24016844"></a>Langballe EM, Engdahl B, Nordeng H, Ballard C, Aarsland D, Selbæk G. Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study. <i>Am J Geriatr Psychiatry</i>. 2014;22(4):321-331. doi:10.1016/j.jagp.2013.06.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/24016844/pubmed" id="24016844" target="_blank">24016844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344706">
<a name="26344706"></a>Larsen ER, Damkier P, Pedersen LH, et al; Danish Psychiatric Society; Danish Society of Obstetrics and Gynecology; Danish Paediatric Society; Danish Society of Clinical Pharmacology. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28. doi:10.1111/acps.12479<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/26344706/pubmed" id="26344706" target="_blank">26344706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lauriello.1">
<a name="Lauriello.1"></a>Lauriello J, Campbell AR. Schizophrenia in adults: Pharmacotherapy with long-acting injectable antipsychotic medication. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 7, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10564343">
<a name="10564343"></a>Lee AY. A case of leukocytoclastic vasculitis associated with haloperidol. <i>Clin Exp Dermatol</i>. 1999;24(5):430. doi:10.1046/j.1365-2230.1999.00523.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/10564343/pubmed" id="10564343" target="_blank">10564343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15000267">
<a name="15000267"></a>Lehman AF, Lieberman JA, Dixon LB, et al; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. <i>Am J Psychiatry</i>. 2004;161(2)(suppl):1-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/15000267/pubmed" id="15000267" target="_blank">15000267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-380367">
<a name="380367"></a>Lerner Y, Lwow E, Levitin A, Belmaker RH. Acute high-dose parenteral haloperidol treatment of psychosis. <i>Am J Psychiatry</i>. 1979;136(8):1061-1064.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/380367/pubmed" id="380367" target="_blank">380367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23146619">
<a name="23146619"></a>Lertxundi U, Hernandez R, Medrano J, Domingo-Echaburu S, García M, Aguirre C. Antipsychotics and seizures: higher risk with atypicals? <i>Seizure</i>. 2013;22(2):141-143. doi:10.1016/j.seizure.2012.10.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/23146619/pubmed" id="23146619" target="_blank">23146619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18849294">
<a name="18849294"></a>Levine SZ, Rabinowitz J. Trajectories and antecedents of treatment response over time in early-episode psychosis. <i>Schizophr Bull</i>. 2010;36(3):624-632. doi:10.1093/schbul/sbn120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/18849294/pubmed" id="18849294" target="_blank">18849294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18391612">
<a name="18391612"></a>Lohr L. Chemotherapy-induced nausea and vomiting. <i>Cancer J</i>. 2008;14(2):85-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/18391612/pubmed" id="18391612" target="_blank">18391612</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22544013">
<a name="22544013"></a>MacDonald K, Wilson M, Minassian A, et al. A naturalistic study of intramuscular haloperidol versus intramuscular olanzapine for the management of acute agitation. <i>J Clin Psychopharmacol</i>. 2012;32(3):317-322.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/22544013/pubmed" id="22544013" target="_blank">22544013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35274188">
<a name="35274188"></a>Madariaga A, Lau J, Ghoshal A, et al. MASCC multidisciplinary evidence-based recommendations for the management of malignant bowel obstruction in advanced cancer. <i>Support Care Cancer</i>. 2022;30(6):4711-4728. doi:10.1007/s00520-022-06889-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/35274188/pubmed" id="35274188" target="_blank">35274188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15138897">
<a name="15138897"></a>Maddalena AS, Fox M, Hofmann M, Hock C. Esophageal dysfunction on psychotropic medication. A case report and literature review. <i>Pharmacopsychiatry</i>. 2004;37(3):134-138.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/15138897/pubmed" id="15138897" target="_blank">15138897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4008674">
<a name="4008674"></a>Magliozzi JR, Gillespie H, Lombrozo L, Hollister LE. Mood alteration following oral and intravenous haloperidol and relationship to drug concentration in normal subjects. <i>J Clin Pharmacology</i>. 1985;25(4):285-290.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/4008674/pubmed" id="4008674" target="_blank">4008674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23926422">
<a name="23926422"></a>Maneeton B, Maneeton N, Srisurapanont M, Chittawatanarat K. Quetiapine versus haloperidol in the treatment of delirium: a double-blind, randomized, controlled trial. <i>Drug Des Devel Ther</i>. 2013;7:657-667. doi: 10.2147/DDDT.S45575.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/23926422/pubmed" id="23926422" target="_blank">23926422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15285957">
<a name="15285957"></a>Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. <i>Am J Psychiatry</i>. 2004;161(8):1334-1349.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/15285957/pubmed" id="15285957" target="_blank">15285957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7569118">
<a name="7569118"></a>Marsh SJ, Dolson GM. Rhabdomyolysis and acute renal failure during high-dose haloperidol therapy. <i>Ren Fail</i>. 1995;17(4):475-478. doi:10.3109/08860229509037611<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/7569118/pubmed" id="7569118" target="_blank">7569118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26818629">
<a name="26818629"></a>Marshall J, Herzig SJ, Howell MD, et al. Antipsychotic utilization in the intensive care unit and in transitions of care. <i>J Crit Care</i>. 2016;33:119-124. doi: 10.1016/j.jcrc.2015.12.017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/26818629/pubmed" id="26818629" target="_blank">26818629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12190212">
<a name="12190212"></a>Martinez M, Devenport L, Saussy J, Martinez J. Drug-associated heat stroke. <i>South Med J</i>. 2002;95(8):799-802.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/12190212/pubmed" id="12190212" target="_blank">12190212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28978587">
<a name="28978587"></a>Masiran R. Persistent oromandibular dystonia and angioedema secondary to haloperidol. <i>BMJ Case Rep</i>. 2017;2017:bcr2017220817. Published Oct 4, 2017. doi:10.1136/bcr-2017-220817<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/28978587/pubmed" id="28978587" target="_blank">28978587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25786075">
<a name="25786075"></a>Maust DT, Kim HM, Seyfried LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. <i>JAMA Psychiatry</i>. 2015;72(5):438-445. doi:10.1001/jamapsychiatry.2014.3018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/25786075/pubmed" id="25786075" target="_blank">25786075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17195735">
<a name="17195735"></a>McClellan J, Kowatch R, Findling RL; Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. <i>J Am Acad Child Adolesc Psychiatry</i>. 2007;46(1):107-125.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/17195735/pubmed" id="17195735" target="_blank">17195735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23972700">
<a name="23972700"></a>McClellan J, Stock S; American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. <i>J Am Acad Child Adolesc Psychiatry</i>. 2013;52(9):976-990. doi:10.1016/j.jaac.2013.02.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/23972700/pubmed" id="23972700" target="_blank">23972700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8601548">
<a name="8601548"></a>McElroy SL, Keck PE, Stanton SP, Tugrul KC, Bennett JA, Strakowski SM. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. <i>J Clin Psychiatry</i>. 1996;57(4):142-146.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/8601548/pubmed" id="8601548" target="_blank">8601548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16822092">
<a name="16822092"></a>McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. <i>J Clin Psychiatry</i>. 2006;67(suppl 5):15-18.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/16822092/pubmed" id="16822092" target="_blank">16822092</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24846035">
<a name="24846035"></a>McEvoy JP, Byerly M, Hamer RM, et al. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial [published correction appears in <i>JAMA</i>. 2014;312(14):1473.] <i>JAMA</i>. 2014;311(19):1978-1987.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/24846035/pubmed" id="24846035" target="_blank">24846035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-McVoy.1">
<a name="McVoy.1"></a>McVoy M, Findling RL, eds. <i>Clinical Manual of Child and Adolescent Psychopharmacology</i>. 3rd ed. Amer Psychiatric Pub; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mehrizi.1">
<a name="Mehrizi.1"></a>Mehrizi M, Fontem RF, Gearhart TR, Pascuzzi RM. <i>Medications and Myasthenia Gravis (a Reference for Health Care Professionals)</i>. Indiana University School of Medicine's Department of Neurology; 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-91324">
<a name="91324"></a>Mehta D, Mehta S, Petit J, Shriner W. Cardiac arrhythmia and haloperidol. <i>Am J Psychiatry</i>. 1979;136(11):1468-1469. doi:10.1176/ajp.136.11.1468<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/91324/pubmed" id="91324" target="_blank">91324</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7544674">
<a name="7544674"></a>Mercadante S. Bowel obstruction in home-care cancer patients: 4 years experience. <i>Support Care Cancer</i>. 1995;3(3):190-193.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/7544674/pubmed" id="7544674" target="_blank">7544674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mercadante.1">
<a name="Mercadante.1"></a>Mercadante S. Palliative care of bowel obstruction in cancer patients. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 21, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20394022">
<a name="20394022"></a>Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? <i>J Hosp Med</i>. 2010;5(4):E8-E16.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/20394022/pubmed" id="20394022" target="_blank">20394022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32265601">
<a name="32265601"></a>Meyers RS, Thackray J, Matson KL, et al. <i>K</i>ey Potentially <i>I</i>nappropriate <i>D</i>rugs in Pediatrics: The KIDs List. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32670542">
<a name="32670542"></a>Moncrieff J, Gupta S, Horowitz MA. Barriers to stopping neuroleptic (antipsychotic) treatment in people with schizophrenia, psychosis or bipolar disorder. <i>Ther Adv Psychopharmacol</i>. Published online July 6, 2020. doi:10.1177/2045125320937910<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/32670542/pubmed" id="32670542" target="_blank">32670542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Moore.1">
<a name="Moore.1"></a>Moore GP, Moore MJ. Assessment and emergency management of the acutely agitated or violent adult. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 7, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8102845">
<a name="8102845"></a>Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale tardive dyskinesia study. <i>Arch Gen Psychiatry</i>. 1993;50(9):723-733. doi:10.1001/archpsyc.1993.01820210057007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/8102845/pubmed" id="8102845" target="_blank">8102845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20187598">
<a name="20187598"></a>Muench J, Hamer AM. Adverse effects of antipsychotic medications. <i>Am Fam Physician</i>. 2010;81(5):617-622.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/20187598/pubmed" id="20187598" target="_blank">20187598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24290467">
<a name="24290467"></a>Murphy TK, Lewin AB, Storch EA, Stock S; American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with tic disorders. <i>J Am Acad Child Adolesc Psychiatry</i>. 2013;52(12):1341-1359.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/24290467/pubmed" id="24290467" target="_blank">24290467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22772698">
<a name="22772698"></a>Muzyk AJ, Cvelich RG, Kincaid BR, Preud'homme XA. Angioedema occurring in patient prescribed iloperidone and haloperidol: a cross-sensitivity reaction to antipsychotics from different chemical classes. <i>J Neuropsychiatry Clin Neurosci</i>. 2012;24(2):E40-E41. doi:10.1176/appi.neuropsych.11040094<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/22772698/pubmed" id="22772698" target="_blank">22772698</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26180871">
<a name="26180871"></a>National Collaborating Centre for Mental Health; National Institute for Health and Care Excellence. Violence and aggression: short-term management in mental health, health and community settings: updated edition. London, UK: British Psychological Society; 2015. https://www.nice.org.uk/guidance/ng10/resources/violence-and-aggression-shortterm-management-in-mental-health-health-and-community-settings-1837264712389. Accessed August 14, 2015.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/26180871/pubmed" id="26180871" target="_blank">26180871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26065063">
<a name="26065063"></a>National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health. Psychosis and schizophrenia in children and young people: recognition and management. 2013. Available at https://www.nice.org.uk/guidance/cg155.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/26065063/pubmed" id="26065063" target="_blank">26065063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32186837">
<a name="32186837"></a>National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health. Psychosis and schizophrenia in children and young people: recognition and management. 2016. https://www.nice.org.uk/guidance/cg155
                     <span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/32186837/pubmed" id="32186837" target="_blank">32186837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15998156">
<a name="15998156"></a>Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. <i>CNS Drugs</i>. 2005;19 Suppl 1:1-93. doi:10.2165/00023210-200519001-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/15998156/pubmed" id="15998156" target="_blank">15998156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17671284">
<a name="17671284"></a>Newport DJ, Calamaras MR, DeVane CL, et al, “Atypical Antipsychotic Administration During Late Pregnancy: Placental Passage and Obstetrical Outcomes,” <i>Am J Psychiatry</i>, 2007, 164(8):1214-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/17671284/pubmed" id="17671284" target="_blank">17671284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22854034">
<a name="22854034"></a>Nielsen RE, Wallenstein Jensen SO, Nielsen J. Neuroleptic malignant syndrome-an 11-year longitudinal case-control study. <i>Can J Psychiatry</i>. 2012;57(8):512-518. doi:10.1177/070674371205700810<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/22854034/pubmed" id="22854034" target="_blank">22854034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15231461">
<a name="15231461"></a>Nobay F, Simon BC, Levitt MA, Dresden GM. A prospective, double-blind, randomized trial of midazolam versus haloperidol versus lorazepam in the chemical restraint of violent and severely agitated patients. <i>Acad Emerg Med</i>. 2004;11(7):744-749.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/15231461/pubmed" id="15231461" target="_blank">15231461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22533871">
<a name="22533871"></a>Nunes LV, Moreira HC, Razzouk D, Nunes SO, Mari Jde J. Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review. <i>J Sex Marital Ther</i>. 2012;38(3):281-301. doi:10.1080/0092623X.2011.606883<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/22533871/pubmed" id="22533871" target="_blank">22533871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10534216">
<a name="10534216"></a>O'Brien JM, Rockwood RP, Suh KI. Haloperidol-induced torsade de pointes. <i>Ann Pharmacother</i>. 1999;33(10):1046-1050. doi:10.1345/aph.19017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/10534216/pubmed" id="10534216" target="_blank">10534216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17012695">
<a name="17012695"></a>Olfson M, Marcus SC, Corey-Lisle P, Tuomari AV, Hines P, L'Italien GJ. Hyperlipidemia following treatment with antipsychotic medications. <i>Am J Psychiatry</i>. 2006;163(10):1821-1825. doi:10.1176/ajp.2006.163.10.1821<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/17012695/pubmed" id="17012695" target="_blank">17012695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14565800">
<a name="14565800"></a>O'Neill JL, Remington TL. Drug-induced esophageal injuries and dysphagia. <i>Ann Pharmacother</i>. 2003;37(11):1675-1684. doi:10.1345/aph.1D056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/14565800/pubmed" id="14565800" target="_blank">14565800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28758203">
<a name="28758203"></a>Ostinelli EG, Brooke-Powney MJ, Li X, Adams CE. Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). <i>Cochrane Database Syst Rev.</i> 2017;7:CD009377. doi: 10.1002/14651858.CD009377.pub3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/28758203/pubmed" id="28758203" target="_blank">28758203</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22196314">
<a name="22196314"></a>Pappadopulos E, Rosato NS, Correll CU, et al. Experts' recommendations for treating maladaptive aggression in youth. <i>J Child Adolesc Psychopharmacol</i>. 2011;21(6):505-515. doi:10.1089/cap.2010.0128<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/22196314/pubmed" id="22196314" target="_blank">22196314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29592958">
<a name="29592958"></a>Park Y, Bateman BT, Kim DH, et al. Use of haloperidol versus atypical antipsychotics and risk of in-hospital death in patients with acute myocardial infarction: cohort study. <i>BMJ</i>. 2018;360:k1218. doi:10.1136/bmj.k1218<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/29592958/pubmed" id="29592958" target="_blank">29592958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31325958">
<a name="31325958"></a>Patterson-Lomba O, Ayyagari R, Carroll B. Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis. <i>BMC Neurol</i>. 2019;19(1):174. Published 2019 Jul 20. doi:10.1186/s12883-019-1385-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/31325958/pubmed" id="31325958" target="_blank">31325958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9735957">
<a name="9735957"></a>Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic malignant syndrome: a review. <i>Psychiatr Serv</i>. 1998;49(9):1163-1172. doi:10.1176/ps.49.9.1163<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/9735957/pubmed" id="9735957" target="_blank">9735957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24688758">
<a name="24688758"></a>Perera MA, Yogaratnam J. De Novo delayed onset hypothermia secondary to therapeutic doses of risperidone in bipolar affective disorder. <i>Ther Adv Psychopharmacol</i>. 2014;4(2):70-74. doi:10.1177/2045125313507740<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/24688758/pubmed" id="24688758" target="_blank">24688758</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11888352">
<a name="11888352"></a>Pisani F, Oteri G, Costa C, Di Raimondo G, Di Perri R. Effects of psychotropic drugs on seizure threshold. <i>Drug Saf</i>. 2002;25(2):91-110. doi:10.2165/00002018-200225020-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/11888352/pubmed" id="11888352" target="_blank">11888352</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Post.1">
<a name="Post.1"></a>Post RM. Bipolar disorder in adults: Choosing maintenance treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 30, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31061208">
<a name="31061208"></a>Pringsheim T, Okun MS, Müller-Vahl K, et al; Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology (AAN). Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. <i>Neurology</i>. 2019;92(19):896-906.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/31061208/pubmed" id="31061208" target="_blank">31061208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31010557">
<a name="31010557"></a>Raffi ER, Nonacs R, Cohen LS. Safety of psychotropic medications during pregnancy. <i>Clin Perinatol</i>. 2019;46(2):215-234. doi:10.1016/j.clp.2019.02.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/31010557/pubmed" id="31010557" target="_blank">31010557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19454032">
<a name="19454032"></a>Reade MC, O'Sullivan K, Bates S, Goldsmith D, Ainslie WR, Bellomo R. Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial. <i>Crit Care</i>. 2009;13(3):R75. doi: 10.1186/cc7890.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/19454032/pubmed" id="19454032" target="_blank">19454032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32671642">
<a name="32671642"></a>Remelli F, Bugada M, Matteucci G, et al. An unwanted reaction by the use of Haloperidol in hyperkinetic delirium [published online ahead of print July 15, 2020]. <i>Aging Clin Exp Res</i>. 2020;10.1007/s40520-020-01649-2. doi:10.1007/s40520-020-01649-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/32671642/pubmed" id="32671642" target="_blank">32671642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15949658">
<a name="15949658"></a>Remington G, Chue P, Stip E, Kopala L, Girard T, Christensen B. The crossover approach to switching antipsychotics: what is the evidence? <i>Schizophr Res</i>. 2005;76(2-3):267-272. doi: 10.1016/j.schres.2005.01.009.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/15949658/pubmed" id="15949658" target="_blank">15949658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27133416">
<a name="27133416"></a>Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. <i>Am J Psychiatry</i>. 2016;173(5):543-546. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.2015.173501. Accessed May 26, 2016. doi: 10.1176/appi.ajp.2015.173501.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/27133416/pubmed" id="27133416" target="_blank">27133416</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24930415">
<a name="24930415"></a>Reznik I, Loewenthal R, Kotler M, Apter I, Mester R, Weizman A. Granulocytopenia associated with neuroleptic therapy in a patient with benign familial leukopenia. <i>Int J Psychiatry Clin Pract</i>. 2003;7(4):277-280. doi:10.1080/13651500310002977<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/24930415/pubmed" id="24930415" target="_blank">24930415</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10340682">
<a name="10340682"></a>Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. <i>J Clin Psychiatry</i>. 1999;60 suppl 10:5-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/10340682/pubmed" id="10340682" target="_blank">10340682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8778681">
<a name="8778681"></a>Risch SC. Pathophysiology of schizophrenia and the role of newer antipsychotics. <i>Pharmacotherapy</i>. 1996;16(1 pt 2):11-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/8778681/pubmed" id="8778681" target="_blank">8778681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14999113">
<a name="14999113"></a>Roden DM. Drug-induced prolongation of the QT interval. <i>N Engl J Med</i>. 2004;350(10):1013-1022. doi:10.1056/NEJMra032426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/14999113/pubmed" id="14999113" target="_blank">14999113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21445724">
<a name="21445724"></a>Roessner V, Plessen KJ, Rothenberger A, et al; ESSTS Guidelines Group. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment [published correction appears in <i>Eur Child Adolesc Psychiatry</i>. 2011;20(7):377]. <i>Eur Child Adolesc Psychiatry</i>. 2011;20(4):173-196.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/21445724/pubmed" id="21445724" target="_blank">21445724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14645311">
<a name="14645311"></a>Rosenheck R, Perlick D, Bingham S, et al; Department of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. <i>JAMA</i>. 2003;290(20):2693-2702. doi: 10.1001/jama.290.20.2693.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/14645311/pubmed" id="14645311" target="_blank">14645311</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12091192">
<a name="12091192"></a>Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. <i>Am J Psychiatry</i>. 2002;159(7):1146-1154. doi: 10.1176/appi.ajp.159.7.1146.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/12091192/pubmed" id="12091192" target="_blank">12091192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25082252">
<a name="25082252"></a>Sadibašić B, Macić-Džanković A, Šabić A, Torlak B, Lastrić G, Ćustović A. The incidence of dyslipidemia (hypertriglyceridemia and hypercholesterolemia) in patients treated with the new generation of antipsychotic drugs compared to conventional therapy. <i>Med Glas (Zenica)</i>. 2014;11(2):350-355.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/25082252/pubmed" id="25082252" target="_blank">25082252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31142911">
<a name="31142911"></a>Şahan E. Haloperidol-related neutropenia. <i>Indian J Psychiatry</i>. 2019;61(3):307-310. doi:10.4103/psychiatry.IndianJPsychiatry_152_18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/31142911/pubmed" id="31142911" target="_blank">31142911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12485307">
<a name="12485307"></a>Sassa T, Suhara T, Ikehira H, et al. 19F-magnetic resonance spectroscopy and chemical shift imaging for schizophrenic patients using haloperidol decanoate. <i>Psychiatry Clin Neurosci</i>. 2002;56(6):637-642.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/12485307/pubmed" id="12485307" target="_blank">12485307</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16554257">
<a name="16554257"></a>Scahill L, Erenberg G, Berlin CM Jr, et al; Tourette Syndrome Association Medical Advisory Board: Practice Committee. Contemporary assessment and pharmacotherapy of Tourette syndrome. <i>NeuroRx</i>. 2006;3(2):192-206.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/16554257/pubmed" id="16554257" target="_blank">16554257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7831996">
<a name="7831996"></a>Scherer J, Tatsch K, Schwarz J, Oertel WH, Konjarczyk M, Albus M. D2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects. <i>Acta Psychiatr Scand</i>. 1994;90(4):266-268. doi:10.1111/j.1600-0447.1994.tb01591.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/7831996/pubmed" id="7831996" target="_blank">7831996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15782087">
<a name="15782087"></a>Schieveld JN, Leentjens AF. Delirium in severely ill young children in the pediatric intensive care unit (PICU).<i> J Am Acad Child Adolesc Psychiatry</i>. 2005;44(4):392-394.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/15782087/pubmed" id="15782087" target="_blank">15782087</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20689925">
<a name="20689925"></a>Schieveld JN, Staal M, Voogd L, Fincken J, Vos G, van Os J. Refractory agitation as a marker for pediatric delirium in very young infants at a pediatric intensive care unit. <i>Intensive Care Med</i>. 2010;36(11):1982-1983. doi:10.1007/s00134-010-1989-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/20689925/pubmed" id="20689925" target="_blank">20689925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17457571">
<a name="17457571"></a>Schieveld JN, Leroy PL, van Os J, Nicolai J, Vos GD, Leentjens AF. Pediatric delirium in critical illness: phenomenology, clinical correlates and treatment response in 40 cases in the pediatric intensive care unit. <i>Intensive Care Med</i>. 2007;33(6):1033-1040.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/17457571/pubmed" id="17457571" target="_blank">17457571</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17325327">
<a name="17325327"></a>Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients [published correction appears in <i>CMAJ</i>. 2007;176(11):1613]. <i>CMAJ</i>. 2007;176(5):627-632. doi:10.1503/cmaj.061250<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/17325327/pubmed" id="17325327" target="_blank">17325327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16234500">
<a name="16234500"></a>Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. <i>JAMA</i>. 2005;294(15):1934-1943. doi:10.1001/jama.294.15.1934<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/16234500/pubmed" id="16234500" target="_blank">16234500</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31425493">
<a name="31425493"></a>Schoretsanitis G, Westin AA, Deligiannidis KM, Spigset O, Paulzen M. Excretion of antipsychotics into the amniotic fluid, umbilical cord blood, and breast milk: a systematic critical review and combined analysis. <i>Ther Drug Monit</i>. 2020;42(2):245-254. doi:10.1097/FTD.0000000000000692<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/31425493/pubmed" id="31425493" target="_blank">31425493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19213967">
<a name="19213967"></a>Seitz DP, Gill SS. Neuroleptic malignant syndrome complicating antipsychotic treatment of delirium or agitation in medical and surgical patients: case reports and a review of the literature. <i>Psychosomatics</i>. 2009;50(1):8-15. doi:10.1176/appi.psy.50.1.8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/19213967/pubmed" id="19213967" target="_blank">19213967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6937455">
<a name="6937455"></a>Serrano AC, “Haloperidol - Its Use in Children,” <i>J Clin Psychiatry</i>, 1981, 42(4):154-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/6937455/pubmed" id="6937455" target="_blank">6937455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21191308">
<a name="21191308"></a>Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. <i>Int Clin Psychopharmacol</i>. 2011;26(3):130-140. doi:10.1097/YIC.0b013e328341e434<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/21191308/pubmed" id="21191308" target="_blank">21191308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1933763">
<a name="1933763"></a>Sethna R, Notkin R. Haloperidol-induced bronchospasm. <i>Can J Psychiatry</i>. 1991;36(7):525-526. doi:10.1177/070674379103600712<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/1933763/pubmed" id="1933763" target="_blank">1933763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2738729">
<a name="2738729"></a>Sexson WR, Barak Y. Withdrawal emergent syndrome in an infant associated with maternal haloperidol therapy. <i>J Perinatol</i>. 1989;9(2):170-172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/2738729/pubmed" id="2738729" target="_blank">2738729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25183567">
<a name="25183567"></a>Slooff VD, Spaans E, van Puijenbroek E, et al. Adverse events of haloperidol for the treatment of delirium in critically ill children. <i>Intensive Care Med</i>. 2014;40(10):1602-1603.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/25183567/pubmed" id="25183567" target="_blank">25183567</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29239979">
<a name="29239979"></a>Slooff VD, van den Dungen DK, van Beusekom BS, et al. Monitoring haloperidol plasma concentration and associated adverse events in critically ill children with delirium: first results of a clinical protocol aimed to monitor efficacy and safety. <i>Pediatr Crit Care Med</i>. 2018;19(2):e112-e119. doi:10.1097/PCC.0000000000001414<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/29239979/pubmed" id="29239979" target="_blank">29239979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23639666">
<a name="23639666"></a>Smith HA, Brink E, Fuchs DC, Ely EW, Pandharipande PP. Pediatric delirium: monitoring and management in the pediatric intensive care unit. <i>Pediatr Clin North Am</i>. 2013;60(3):741-760. doi:10.1016/j.pcl.2013.02.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/23639666/pubmed" id="23639666" target="_blank">23639666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17390261">
<a name="17390261"></a>Soares-Weiser K, Fernandez HH. Tardive dyskinesia. <i>Semin Neurol</i>. 2007;27(2):159-169.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/17390261/pubmed" id="17390261" target="_blank">17390261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28721057">
<a name="28721057"></a>Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. <i>Ther Clin Risk Manag</i>. 2017;13:757-777. doi:10.2147/TCRM.S117321<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/28721057/pubmed" id="28721057" target="_blank">28721057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29439776">
<a name="29439776"></a>Solmi M, Pigato G, Kane JM, Correll CU. Clinical risk factors for the development of tardive dyskinesia. <i>J Neurol Sci</i>. 2018;389:21-27. doi:10.1016/j.jns.2018.02.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/29439776/pubmed" id="29439776" target="_blank">29439776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23343447">
<a name="23343447"></a>Spanarello S, La Ferla T. The pharmacokinetics of long-acting antipsychotic medications. <i>Curr Clin Pharmacol</i>. 2014;9(3):310-317. doi:10.2174/15748847113089990051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/23343447/pubmed" id="23343447" target="_blank">23343447</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Steinman.1">
<a name="Steinman.1"></a>Steinman M, Reeve E. Deprescribing. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 30, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18628446">
<a name="18628446"></a>Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. <i>Ann Pharmacother</i>. 2008;42(9):1290-1297. doi:10.1345/aph.1L066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/18628446/pubmed" id="18628446" target="_blank">18628446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stovall.2019">
<a name="Stovall.2019"></a>Stovall J. Bipolar mania and hypomania in adults: choosing pharmacology. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 10, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15226162">
<a name="15226162"></a>Straus SM, Bleumink GS, Dieleman JP, et al. Antipsychotics and the risk of sudden cardiac death [published correction appears in <i>Arch Intern Med</i>. 2004;164(17):1839]. <i>Arch Intern Med</i>. 2004;164(12):1293-1297. doi:10.1001/archinte.164.12.1293<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/15226162/pubmed" id="15226162" target="_blank">15226162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17541044">
<a name="17541044"></a>Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. <i>Am J Psychiatry</i>. 2007;164(6):870-876.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/17541044/pubmed" id="17541044" target="_blank">17541044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30192094">
<a name="30192094"></a>Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. <i>World Psychiatry</i>. 2018;17(3):341-356. doi:10.1002/wps.20567<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/30192094/pubmed" id="30192094" target="_blank">30192094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stroup.1">
<a name="Stroup.1"></a>Stroup TS, Marder S. Schizophrenia in adults: Maintenance therapy and side effect management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 28, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Suh.1">
<a name="Suh.1"></a>Suh KN, Keystone JS. Treatment of delusional infestation. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 30, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31846256">
<a name="31846256"></a>
<i>Surveillance report 2016 – Psychosis and schizophrenia in children and young people: recognition and management (2013) NICE guideline CG155</i>. London: National Institute for Health and Care Excellence (UK); November 3, 2016.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/31846256/pubmed" id="31846256" target="_blank">31846256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28044008">
<a name="28044008"></a>Takeuchi H, Kantor N, Uchida H, Suzuki T, Remington G. Immediate vs gradual discontinuation in antipsychotic switching: a systematic review and meta-analysis. <i>Schizophr Bull</i>. 2017;43(4):862-871. doi: 10.1093/schbul/sbw171.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/28044008/pubmed" id="28044008" target="_blank">28044008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tesar.1988">
<a name="Tesar.1988"></a>Tesar GE, Stern TA. Analytic reviews: rapid tranquilization of the agitated intensive care unit patient. <i>J Intensive Care Med.</i> 1988;3(4):195-201. doi: 10.1177/088506668800300403</div>
</li>
<li>
<div class="reference">
                  Teva-Haloperidol (haloperidol) [product monograph]. Toronto, Ontario, Canada: Teva Canada Limited; August 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tietze.1">
<a name="Tietze.1"></a>Tietze KJ, Fuchs B. Sedative-analgesic medications in critically ill adults: Properties, dose regimens, and adverse effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 5, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32929996">
<a name="32929996"></a>Tisdale JE, Chung MK, Campbell KB, et al. Drug-induced arrhythmias: a scientific statement from the American Heart Association. <i>Circulation</i>. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/32929996/pubmed" id="32929996" target="_blank">32929996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23716032">
<a name="23716032"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients [published correction appears in <i>Circ Cardiovasc Qual Outcomes</i>. 2013;6(6):e57]. <i>Circ Cardiovasc Qual Outcomes</i>. 2013;6(4):479-487. doi:10.1161/CIRCOUTCOMES.113.000152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/23716032/pubmed" id="23716032" target="_blank">23716032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24803473">
<a name="24803473"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients [published correction appears in <i>Circ Cardiovasc Qual Outcomes</i>. 2014;7(6):981]. <i>Circ Cardiovasc Qual Outcomes</i>. 2014;7(3):381-390. doi:10.1161/CIRCOUTCOMES.113.000651<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/24803473/pubmed" id="24803473" target="_blank">24803473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11249804">
<a name="11249804"></a>Tohen M, Jacobs TG, Feldman PD. Onset of action of antipsychotics in the treatment of mania. <i>Bipolar Disord</i>. 2000;2(3 Pt 2):261-268. doi:10.1034/j.1399-5618.2000.20307.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/11249804/pubmed" id="11249804" target="_blank">11249804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27298071">
<a name="27298071"></a>Tolppanen AM, Koponen M, Tanskanen A, et al. Antipsychotic use and risk of hospitalization or death due to pneumonia in persons with and those without Alzheimer disease. <i>Chest</i>. 2016;150(6):1233-1241. doi:10.1016/j.chest.2016.06.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/27298071/pubmed" id="27298071" target="_blank">27298071</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22626633">
<a name="22626633"></a>Trollor JN, Chen X, Chitty K, Sachdev PS. Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics. <i>Br J Psychiatry</i>. 2012;201(1):52-56. doi:10.1192/bjp.bp.111.105189<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/22626633/pubmed" id="22626633" target="_blank">22626633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24898718">
<a name="24898718"></a>Turkel SB, Hanft A. The pharmacologic management of delirium in children and adolescents. <i>Paediatr Drugs</i>. 2014;16(4):267-274.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/24898718/pubmed" id="24898718" target="_blank">24898718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31135176">
<a name="31135176"></a>Uguz f. Adverse events in a breastfed infant exposed to risperidone and haloperidol. <i>Breastfeed Med</i>. 2019;14(9):683-684. doi:10.1089/bfm.2019.0093<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/31135176/pubmed" id="31135176" target="_blank">31135176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26407790">
<a name="26407790"></a>Vancampfort D, Stubbs B, Mitchell AJ, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. <i>World Psychiatry</i>. 2015;14(3):339-347. doi:10.1002/wps.20252<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/26407790/pubmed" id="26407790" target="_blank">26407790</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10473482">
<a name="10473482"></a>van Harten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. <i>BMJ</i>. 1999;319(7210):623-626. doi:10.1136/bmj.319.7210.623<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/10473482/pubmed" id="10473482" target="_blank">10473482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17401555">
<a name="17401555"></a>van Marum RJ, Wegewijs MA, Loonen AJ, Beers E. Hypothermia following antipsychotic drug use. <i>Eur J Clin Pharmacol</i>. 2007;63(6):627-631. doi:10.1007/s00228-007-0294-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/17401555/pubmed" id="17401555" target="_blank">17401555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21346608">
<a name="21346608"></a>Veselinović T, Schorn H, Vernaleken IB, Schiffl K, Klomp M, Gründer G. Impact of different antidopaminergic mechanisms on the dopaminergic control of prolactin secretion. <i>J Clin Psychopharmacol</i>. 2011;31(2):214-220. doi:10.1097/JCP.0b013e31820e4832<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/21346608/pubmed" id="21346608" target="_blank">21346608</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23858394">
<a name="23858394"></a>Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. <i>Tremor Other Hyperkinet Mov (N Y)</i>. 2013;3:tre-03-161-4138-1. doi:10.7916/D88P5Z71<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/23858394/pubmed" id="23858394" target="_blank">23858394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27780320">
<a name="27780320"></a>Welten CC, Koeter MW, Wohlfarth TD, et al. Early nonresponse in the antipsychotic treatment of acute mania: a criterion for reconsidering treatment? Results from an individual patient data meta-analysis. <i>J Clin Psychiatry</i>. 2016;77(9):e1117-e1123. doi:10.4088/JCP.15r10051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/27780320/pubmed" id="27780320" target="_blank">27780320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22114630">
<a name="22114630"></a>Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. <i>Dtsch Arztebl Int</i>. 2011;108(41):687-693. doi:10.3238/arztebl.2011.0687<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/22114630/pubmed" id="22114630" target="_blank">22114630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28643331">
<a name="28643331"></a>Westin AA, Brekke M, Molden E, Skogvoll E, Castberg I, Spigset O. Treatment with antipsychotics in pregnancy: changes in drug disposition. <i>Clin Pharmacol Ther</i>. 2018;103(3):477-484. doi:10.1002/cpt.770<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/28643331/pubmed" id="28643331" target="_blank">28643331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6786603">
<a name="6786603"></a>Whalley LJ, Blain PG, and Prime JK, “Haloperidol Secreted in Breast Milk,” <i>Br Med J (Clin Res Ed)</i>, 1981, 282(6278):1746-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/6786603/pubmed" id="6786603" target="_blank">6786603</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4887476">
<a name="4887476"></a>Willner MM, Gordon LE. Psychotropic drugs in children. Pharmacotherapy as an adjunct to counseling or psychotherapy. <i>Clin Pediatr (Phila)</i>. 1969;8(4):193-200.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/4887476/pubmed" id="4887476" target="_blank">4887476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21601409">
<a name="21601409"></a>Wilson MP, MacDonald K, Vilke GM, Feifel D. A comparison of the safety of olanzapine and haloperidol in combination with benzodiazepines in emergency department patients with acute agitation. <i>J Emerg Med</i>. 2012b;43(5):790-797.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/21601409/pubmed" id="21601409" target="_blank">21601409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22461918">
<a name="22461918"></a>Wilson MP, Pepper D, Currier GW, Holloman GH Jr, Feifel D. The psychopharmacology of agitation: consensus statement of the American Association for Emergency Psychiatry Project Beta Psychopharmacology Workgroup. <i>West J Emerg Med</i>. 2012a;13(1):26-34. doi: 10.5811/westjem.2011.9.6866.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/22461918/pubmed" id="22461918" target="_blank">22461918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27249081">
<a name="27249081"></a>Wu CS, Wang SC, Yeh IJ, Liu SK. Comparative risk of seizure with use of first- and second-generation antipsychotics in patients with schizophrenia and mood disorders. <i>J Clin Psychiatry</i>. 2016;77(5):e573-e579. doi:10.4088/JCP.15m09898<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/27249081/pubmed" id="27249081" target="_blank">27249081</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22450010">
<a name="22450010"></a>Yasuhara Y, Hirai E, Sakamaki S, et al. Using ultrasonography in the intramuscular injection techniques used for administering drug treatments to schizophrenic patients in Japan. <i>J Med Invest</i>. 2012;59(1-2):213-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/22450010/pubmed" id="22450010" target="_blank">22450010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29536616">
<a name="29536616"></a>Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. <i>Bipolar Disord</i>. 2018;20(2):97-170. doi: 10.1111/bdi.12609.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/29536616/pubmed" id="29536616" target="_blank">29536616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10221361">
<a name="10221361"></a>Yoshida K, Smith B, and Kumar R, “Psychotropic Drugs in Mothers' Milk: A Comprehensive Review of Assay Methods, Pharmacokinetics and of Safety of Breast-Feeding,” <i>J Psychopharmacol</i>, 1999, 13(1):64-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/10221361/pubmed" id="10221361" target="_blank">10221361</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34621607">
<a name="34621607"></a>Youniss L, Thomas M, Davis EAK. Probable haloperidol decanoate-induced fever in an African American with benign ethnic neutropenia: a case report. <i>Ment Health Clin</i>. 2021;11(5):301-304. doi:10.9740/mhc.2021.09.301<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/34621607/pubmed" id="34621607" target="_blank">34621607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36113417">
<a name="36113417"></a>Yuksel JM, Brenner JM, Britton S, Bhatti H, Noviasky J. Optimal injectable haloperidol dose assessment in the older hospitalized inpatient. <i>Ann Pharmacother.</i> 2023;57(6):662-668. doi:10.1177/10600280221124615<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/36113417/pubmed" id="36113417" target="_blank">36113417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23653156">
<a name="23653156"></a>Zirker W, Dorokhine I, Knapp CM, Patel N, Musuku M. Haloperidol overdosing in the treatment of agitated hospitalized older people with delirium: a retrospective chart review from a community teaching hospital. <i>Drugs Aging.</i> 2013;30(8):639-644. doi:10.1007/s40266-013-0087-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/23653156/pubmed" id="23653156" target="_blank">23653156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28936184">
<a name="28936184"></a>Zonnenberg C, Bueno-de-Mesquita JM, Ramlal D, Blom JD. Hypothermia due to antipsychotic medication: a systematic review. <i>Front Psychiatry</i>. 2017;8:165. doi:10.3389/fpsyt.2017.00165<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/28936184/pubmed" id="28936184" target="_blank">28936184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24794843">
<a name="24794843"></a>Zou D, Shao Y, Qin Z, et al. Death due to fulminant neuroleptic malignant syndrome induced by low doses of haloperidol: a rare case. <i>J Forensic Leg Med</i>. 2014;24:12-14. doi:10.1016/j.jflm.2014.02.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/haloperidol-drug-information/abstract-text/24794843/pubmed" id="24794843" target="_blank">24794843</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8516 Version 690.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
